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Bone marrow transplantation has entrenched itself as an indispensable therapeutic 
modality in clinical practice. Its role in the salvage of patients with haematological 
malignancies following ablative cytotoxic chemotherapy is well established. More liberal 
application of this therapeutic modality resulted in the observation that Bone Marrow 
Transplantation (BMT) resulted in a lower relapse rate independent of the cytotoxic 
therapy establishing the entity of the Graft Versus Leukaemia (GVL) effect. This has 
been well documented in both laboratory experiments as well as in clinical practice. 
Three important facets emerged from these observations: 
• BMT allowed for more aggressive chemotherapy to effect eradication of tumour and
minimise relapse 
• the success of BMT raised the potential for the use of this modality to correct
congenital abnormalities of the haematological system 
• Its use in the context of malignancies served to consolidate the anti-tumour effect
which minimised relapse and served as maintenance for tumour surveillance 
However, wider use of this technique has been frustrated by three major factors: 
• Engraftment failure
• the emergence of Graft Versus Host Disease (GVHD)
• The deleterious effects of the conditioning regime and the post-transplantation care
Despite these limitations, its role has been gradually extended to embrace the 
treatment of benign conditions as well as in the treatment of solid visceral 
malignancies. 
DEFINITION AND HISTORY OF BONE MARROW TRANSPLANTATION 
Bone Marrow Transplantation is a well-established clinical therapeutic procedure 
involving the transfer of pleuripotent stem cells. At present, BMT may be performed 
with the individual's own stem cells whence it is referred to as autologous 
transplantation; this also occurs when the transplantation is from an identical twin. BMT 
between individuals of the same species is referred to as allogeneic transplantation. 
Whilst Xenogeneic transplantation (between different species) has been extensively 
performed in laboratory experiments, only a single case has been performed in clinical 
practice for acquired immunodeficiency. At present, only autologous and allogeneic 
transplantation are routinely performed in clinical practice. 
The history of BMT dates back to 1939 when a patient suffering from aplastic anaemia 
was treated with 18 ml of blood from his brother1 . From 1970 to 1990 more than 10000 
BMT have been performed throughout the world
2
. 
The best matching situation for successful BMT is identical twins. In the absence of 
this, HLA identical sibling donor is optimal for allogeneic transplantation. Other options 
for BMT include unrelated but well matched donors and related but less well-matched 
donors. 
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PRETRANSPLANT CONDITIONING USED FOR BMT 
In the first half of the century it was observed that irradiation had profound suppressive 
effects on the immune system
3
. Based on these findings, Total Body Irradiation (TBI) 
was used for preparing recipients for bone marrow and organ transplantation. However, 
it became apparent that very high doses of irradiation were necessary to prevent 
allograft rejections. These high irradiation doses were associated with severe toxicity 
culminating in formidable morbidity and mortality rates
4
• Subsequently, irradiation 
protocols were modified to minimise these effects and fractionated irradiation
administered loco-regionally were implemented to minimise the toxic effects. One of 
these fractionated protocols, Total Lymphoid Irradiation (TU) was used for bone 
marrow and organ transplantation by a group of researchers at Stanford University5· 6. 
Prior to its application to effect immunosuppresion, TU was used in the treatment of 
Hodgkin's Lymphoma. This led to the recognition of the various immunological 
alterations that occurred as a consequence of the treatment. Of significance, TLI 
resulted in a T cell lymphopaenia, a decrease responsiveness of the residual T cells to 
the mitogens Concanavalin A (Con A) and phytohaemagglutinin (PHA), and a 
decreased in vitro mixed lymphocyte reaction (MLR). These observations encouraged 
the use of TU as an immunosuppressant to achieve tolerance to both solid organ 
transplantation and as a therapeutic modality for autoimmune disorders. Subsequent 
laboratory investigations confirmed that TU proved to be an excellent conditioning 
regimen to achieve transplantation tolerance and the studies performed with BMT 








secondary haematological malignancies were rare and infections, barring benign 
herpes zoster10 , were rare. TLI involves irradiating selected parts of the body,
essentially the lymphoid system, with the other organs being shielded by lead blocks. 
The efficacy of the regimen can be increased by widening the TLI field or by adding 1 
to 2 TBI fractions 
11• 
Despite the induction of donor specific tolerance as well as the activation of natural 
suppressor cells, there are some limitations to TLI. There is an optimum time period of 
about 1week after TLI during which transplantation must be performed. If 
transplantation is not performed within this period then the tolerance is less predictable 
and unclear
11• 12. 
IMMUNE RESPONSE AND SELECTION OF THE IMMUNE REPERTOIRE 
Normally, 2 types of immune responses have been recognised that are reactive to 
alloantigens and hence can play a role following BMT: The cellular response, mediated 
by T cells and Natural Killer/ Lymphokine Activated Killer (NK/LAK) cells and the 
humeral response mediated by B cells and antibodies. T cells undergo maturation and 
differentiation in the thymus mainly consequent upon 2 processes; positive and 
negative selection. During positive selection T cells acquiring T cell receptors (TCR's) 
with intermediate affinity for self-MHC will survive. This implies that T cells recognise 
foreign antigens in the context of foreign antigens (peptides) in the context of self-MHC 
molecules. During negative selection T cells with a high affinity for self-MHC molecules 
will be clonally deleted in order to circumvent autoimmune reactions. With these 2 
selection processes, an effective T cell repertoire is formed intrathymically as a result 
of the interactions between TCR's and MHC molecules expressed on thymic epithelial 
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cells in positive selection and, TCR's and MHC molecules expressed on bone marrow 
derived Antigen Presenting Cells (APC) in negative selection. Similar selection 
phenomena are suggested for B cells but are not proven as yet
13
. For NK or LAK cells,
no data is available with respect to their selection or their repertoire. 
THE MINOR LYMPHOCYTE STIMULATING (Mis) SYSTEM 
The negative selection process leading to self tolerance for T cells has been 
investigated using superantigens and transgenic mice. Since the Mis system is crucial 
to the subsequent experiments, it will be discussed in more detail. 
Mis antigens are viral products that are encoded for by open reading frame (orf) in 3 





. These orf products are type II transmembrane glycoproteins that
can bind to MHC class II molecules 16. They can also function as superantigens like
other infectious agents such as bacterial superantigens. In addition to their ability to 
react with T cells by binding with some specific p components of the variable region of 
ap TCR's, they also have the capacity to bind to MHC class II molecules outside the 
peptide binding groove 17· 18. This means that Mis antigens stimulate large proportions of 
T cells expressing specific V TCR's so vigorously that after a period of massive 
proliferation and lymphokine release, T cells die. 
The trimolecular interaction between superantigens usually lead to apoptosis of 
immature T cells and proliferation followed by anergy of mature T cells bearing the 
relevant Vp domains. This occurs in vivo. 
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IMMUNOLOGIC TOLERANCE 
In the early 1950's Peter Medawar and colleagues demonstrated that when neonatal 
mice of strain "A" were injected with lymphohaematopoeitic cells of strain "B" they 
became tolerant to skin grafts from strain "B" but not for skin grafts taken from strain 
"C". This form of neonatally induced tolerance was donor specific and long lived 19· 20. 
The term 'tolerance' is now generally accepted to as a state of non-responsiveness of 
the immune system to an antigenic challenge. There are three main factors that will 
determine whether an individual will elicit an effective immune response or develop 
tolerance. The factors are 
• The nature, dose, route of administration and character of the antigen
• The type of antigen presenting cells
• The maturational phase of the responding lymphocyte
Self-tolerance refers to the destruction or functional inactivation of lymphocytes with 
potential reactivity for self-antigens. This form of tolerance is achieved mainly in the 
thymus for T lymphocytes and probably in the bone marrow for B lymphocytes and is 
therefore frequently referred to as central tolerance. Under certain circumstances 
some self-reactive lymphocytes can undergo inactivation in the peripheral lymphoid 
tissue and this is referred to as peripheral tolerance. 
Allograft acceptance without immunosuppressive therapy is called allotolerance or 
transplantation tolerance. The achievement of the latter remains the challenge in 
transplantation biology. In animal models, various techniques have been developed 
that can achieve transplantation tolerance. As already alluded to, Medawar and 
Billingham showed that tolerance to foreign skin grafts could be acquired and sustained 
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for long periods after innoculation of donor bone marrow cells into neonatal mice 19. 
After this initial achievement of neonatal tolerance, various procedures were developed 
to induce tolerance in adult recipients as well. Unlike neonatal tolerance, a preparative 
protocol is necessary in adult recipients to allow for the successful transfer of 
allogeneic bone marrow to circumvent host immunocompetent cells from rejecting 
donor cells. 
MECHANISMS OF TRANSPLANTATION TOLERANCE 
Four mechanisms of transplantation tolerance have been described and substantiated 
in the literature. 
CLONAL DELETION 
Clonal deletion refers to the physical elimination of specific T cell clones and this 
occurs mainly in the thymus. Bone marrow derived Antigen Presenting Cells (APCs) 
found in the thymic medulla or at the cortico-medullary junction are the most important 
cells that cause the appropriate reactive T cells to die by a process called apoptosis 
(programmed cell death). Amongst these BM derived APCs, the most important 
appears to be the Dendritic cells20. 
Several reports employing transgenic or minor antigen disparate models have 
demonstrated the presence of peripheral tolerance and the mechanisms of peripheral 
tolerance are multiple. 
CLONAL ANERGY 
This term refers to a condition in which lymphocytes become functionally inactivated 
without undergoing physical elimination. Although thymic epithelial cells are also 
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believed to use anergy for tolerance induction, this mechanism is mainly operative in 
the peripheral lymphoid tissues20• 21. Clonal anergy is usually achieved when T cell
receptors are occupied by antigens in the absence of sufficient costimulatory second 
signals22. There is no single molecule or pathway that delivers this costimulation but 
rather a whole group of adhesion molecules and their ligands expressed on 
lymphocytes and antigen presenting cells21· 22 • These include the pairs LFA-1/ICAM,
CD2/LFA-3, VLA-4NCAM-1 and CD28/CTLA4:87 or 88121' 23. The latter molecules




26 and also on activated T cells27• During TCR­
MHC interactions, B7:CD28/CTLA4 costimulatory molecules can be blocked e.g. by 
CTLA4 lg fusion proteins28 . Lafferty reported much earlier that costimulatory molecules 
were important in transplantation immunology as they determined immune responses to 
donor antigens
29
. In most situations, T cell anergy is reversible. This has been 




This term is used to describe the situation where the non-reactivity of the T cells is 
either as a result of antigen inaccessibility (sequestered inside cells or behind 
anatomical barriers) or when the affinity of the TCRs for antigens are too low 
(presented by non professional APCs). With regard to transplantation immunology, it is 
believed that donor grafts that are devoid of donor type professional APCs are 





There is ample evidence that mature T cells can be clonally deleted in the periphery 
and this may also be imparted by Veto cells32 · 33 . 
Veto cells: The term Veto cells is used for cells that are able to delete or inactivate T 
cells only when Veto cells themselves are attacked by these T cells34• Miller was first to 
describe these cells in in vitro experiments33 . The precise identity of Veto cells remain 
to be established. They are thought to effect their action by direct lysis35 or by 




This term is employed to describe the phenomenon where the T cell responsiveness is 
diminished or abrogated either by other cell populations, soluble factors or both. These 
cells and soluble products are commonly termed suppressor cells and suppressor 
factors. Suppressor cells can be antigen or idiotypic specific or natural suppressor 
cells. Natural suppressor cells are believed to block or inhibit the activation of T cells in 
response to different antigenic challenges37. These cells have been demonstrated to 
expand after total lymphoid irradiation or after treatment with cyclophosphamide. The 
phenotype of these cells are not established but surface markers are similar to those 
described for NK cells although they do not demonstrate the same functions37. It is 
believed that some soluble factors or proteins released from NS cells down regulate 
immune responsiveness. 
B cell tolerance: B lymphocytes are dependent on T cells for activation under most 
circumstances, hence humeral tolerance is frequently based on T cell tolerance. 
However, T independent B cell activation may also occur. The experiments performed 
9 
using transgenic mice show that the same mechanisms that allow for T cell tolerance 
are relevant to B cell tolerance38. 
Another mechanism of B cell tolerance entails the exclusion of B cells from the primary 
follicles of lymph nodes and the spleen. The fate of these excluded cells is apoptosis39. 
CHIMAERISM 
Allogeneic BMT can result in chimaerism. This describes the situation where cells from 
the donor persist in the recipient either alone or alongside host bone marrow cells. 
Attaining stable long-term chimaerism requires overcoming rejection which is mediated 
by host type T cells and NK cells and is usually overcome by immunosuppression 
achieved with irradiation or cytotoxic agents40 . Once rejection is overcome, the next 
problem that needs to be resolved is GVHD. 
Stable chimaeras usually remain specifically tolerant for donor and host alloantigens 
but are capable of responding to third party antigens. Chimaeras may either be 
complete, where the donor bone marrow completely replaces the host marrow, or 
mixed, where the donor and recipient marrow coexist. Mixed chimaeras are thought to 
confer superior immunocompetence especially antiviral and antibody responses
41
. 
PROBLEMS INHERENT TO BONE MARROW TRANSPLANTATION 
Bone marrow transplantation mandates a conditioning regime to free spaces or niches 
in the host to accommodate the transplanted stem cells. This mandates a 
preconditioning to "create" this space with either chemotherapy or irradiation
42
. This 
situation does not exist for solid visceral transplantation. 
10 
The immunocompetent cells in the transplant may be directed against antigens present 
on the host tissues leading to GVHD, a situation that is uncommon following solid 
visceral transplantation. BMT is also associated with a period of immunodeficiency. 
In addition to the incompatibility of the major and minor histocompatibility antigens, 
haematopoeitic histocompatibility (Hh) antigens, which are present on marrow cells, are 
also involved in the rejection of Bone marrow grafts
43
• 
REJECTION OF BONE MARROW GRAFTS 
This occurs when mature T cells are removed from the graft or the preconditioning 
regimen is inadequate and is usually consequent upon histocompatibility and or Hh 
antigen mediated. 
Both cellular and humeral factors have been implicated in the rejection of marrow 






• Cytotoxic T cells (CD3+, CDS+)
• NK/LAK cells (CD3-, NK1.1+)
• TNK cells (CD3+, CDS-, NK1.1+)
NK Cells and BM graft rejection 
NK cells are mononuclear cells. Originally described as "null cells", they usually display 
a morphology of large granular lymphocytes (LGL). The definition of NK cells by 
morphology is however inadequate because all LGL's are not NK cells and vice-versa. 
In human peripheral blood and in mice, the spleen is the principal site where NK cells 
11 
are located46• In mice, NK cells are phenotypically CD3-, TCR-, slg-, NK1 +, AsialoGM+, 
CD16 (Fcy111f LGL's. Although NK cells do not express full CD3 molecules, they have 
a CD3 subunit (CD3s) that is incorporated within their Fe receptor structure 47. In 
addition, NK cells express medium affinity IL-2 receptors 47. Functionally, NK cells are 
characterised by their lytic activity against tumour and virally infected cells that are non­
MHC restricted and do not require prior sensitisation48. They also participate in the 
rejection of BM grafts. 
In mice, NK cells originate from and differentiate in the bone marrow. They do not 
require the thymus for their differentiation. The IL-2 and IL-12 are major growth factors 
known to be active in inducing differentiation of NK cells in both humans and in mice49' 
so. 51. The effects of IL-2 may be indirect because the activity of IL-2 on NK cell
maturation can be abrogated when IFN-y and TNF-a are blocked by antibodies. This 
demonstrates that IFN-y and and TNF-a play a role in IL-2 mediated maturation of NK 
cells 51. 52_ 
NK cells are capable of producing lymphokines such as the IFN's, IL-2, IL-3, TNF's, B 
cell growth factors, TGF-p, and GM-CSF and other colony stimulating factors 53' 54. 
NK cells mediate cytotoxicity through their lytic machinery composed of large cytotoxic 
granules. A surface marker, Ly-49, is present on some subset of murine NK cells 55. 
The binding of Ly-49 with MHC class I molecules can result in a negative inhibitory 
signal to NK cells that renders the target cell resistant to NK cell mediated killing 55. 
Rejection of BM grafts cannot occur in hosts if their NK cells are depleted. Much 
evidence proving the role of NK cells in BM rejection has come from experiments with 
SCIO and athymic nude mice. Such mice are able to reject parental or allogeneic BM 
12 
grafts despite being devoid of T and B cells. This suggests that NK cells are not only 
necessary but are sufficient for BM rejection 56. 
T cells and BM graft rejection 
Rejection of BM grafts as mediated by T cells with classical markers such as Co3•, 
Thy1+, CD4+, and CDS+ differ from that mediated by both the target antigens 
recognised and by the kinetics of rejection 57. With NK cells, rejection is effected via the 
Hh antigens and usually occur rapidly 57• For T cells, rejection is directed against the 




• T cells destroy BM grafts by 
either a direct cytotoxic action or indirectly by secreting cytokines that that stimulate 
macrophages to destroy BM cells 60. 
T cells with NK markers (CD3+, NK1 +) and BM rejection 
Although T cells and NK cells are 2 distinct cell types, they may share some common 
markers. Cells expressing both NK and T cell markers are known as TNK cells or T 




. Several reports have indicated that such cells are important
effector cells in the acute rejection of allogeneic and parental BM grafts. These cells 
are said to utilise both TCRa/� for the recognition of MHC antigens and NK1 .1 
receptors for interaction with appropriate ligands on target tissues indicating two 
independent pathways 57' 58. 
Graft Versus Host Disease (GVHD) 
13 
GVHD is a disease due to the immune reactivity exhibited by the donor against host 
alloantigens. It involves a series of interactions between various cells and cytokines of 
the immune system. GVHD frequently occurs as a fatal complication that is still 
considered the principle factor limiting the clinical use of allogeneic BMT. GVHD was 
first observed in irradiated mice receiving allogeneic spleen cells. GVHD, initially, was 
thought to be caused by post-irradiation injury and bone marrow aplasia 
62
. Animals
with GVHD developed a syndrome consisting of alopecia, weight loss, diarrhoea, liver 
abnormalities and ultimately, death. The classical requirements for the development of 
GVHD was set forth in 1956 and are as follows 63: 
• The graft must contain immunocompetent cells
• There must be transplantation barriers between the donor and the host
• The recipient must be immunoincompetent to react immunologically against
the graft
GVHD can be separated into 2 different types based on clinicohistopathological 
criteria; acute and chronic. 
In mice acute GVHD is characterised by weight loss, alopecia erythroderma, hunched 
posture, diarrhoea and death. Amongst these, the most important parameter is weight 
loss. Histologically, epithelial cell necrosis of the main target organs is the sine qua non 
62. The epidermis and hair follicles are injured and necrosed. In the liver, small bile
ducts and periductular epithelium are affected. The base of the intestinal crypts are 
damaged. 
Chronic GVHD is better described by histology than by clinical manifestations. Chronic 
GVHD can follow acute GVHD or can occur without prior acute GVHD. The histological 
14 
features include fibrosis and atrophy of one or more target organs. In the thymus, 
involution of medullary epithelial cells with total effacement of the cortico-medullary 
junction and disappearance of Hassals corpuscles are usually seen 
64
. These can affect 
the thymic environment markedly culminating in defective T cell maturation. 
Subsequently, the thymus is unable to detect and delete autoreactive T cells rendering 
the animal susceptible to the emergence of autoimmune diseases. 
lrnrnunopathogenesis: Initially, GVHD was considered a consequence of T cell 
reactivity. Recent evidence suggests that the immunopathophysiology underlying 
GVHD involves a series of complex interactions in which cellular and cytokine 
components of the immune system are involved 65. The cellular components comprise T 
cells, NK/LAK cells and macrophages. Amongst these, T cells are the prime mediators 
for the initiation of GVHD. NK/LAK cells and macrophages are important in the effector 
phase. The cytokine component of the disease comprise a multiplicity of substances 





performed in murine BM transplantation models involving MHC identical but minor 
antigen disparate mice have shown that during GVHD mRNA transcripts for IL-1 and 
TNFa increased several hundred and 4 - 6 fold respectively in target tissues 66. Tissue
injury during the conditioning period may also result in the release of some 
inflammatory cytokines 68• As a consequence of this, increased MHC expression and
upregulation of adhesion molecules is seen in host tissues. The pathophysiology of 
GVHD is frequently regarded as a cytokine storm 
69
. 
GVHD and minor antigens: There are some conflicting reports regarding the T cell 
subsets responsible for GVHD in MHC compatible but minor antigen mismatched strain 
15 
combinations. Studies where T cells were depleted suggest that CD4+ T cells are 
critical for the development of GVHD 
70
• Other investigators stressed the role of CD8+ T
cells 71. It is now agreed that immunogenetic and environmental factors will dictate 
which subset is important in the pathogenesis of GVHD 72• 
Prevention of GVHD: 
Donor T cell depletion: The most effective way of preventing GVHD is the removal of 
mature T cells from the donor innocula. Two methods are used; either seperation of T 
cells by lectine agglutination or depletion of T cells by coupling using Mab's together 
with either complement or toxins such as ricin. Both these methods are associated with 
a higher incidence of engraftment failure and leukaemia recurrence. 
In vivo activation of Th2 subsets: It is hoped that by activating Th2 cells, the 
activation of Th1 cells will be blocked thereby abrogating GVHD. Stimulation of the Th2 
subset can be accomplished by the injection of IL-4 alone or in combination with high 
doses of IL-2 65. 
Blocking T cell activation: Addition of non-mitogenic antiCD3-F(ab)2 fragments in 
vivo allows T cell functions to be altered without physical elimination 73. Blocking the 
costimulatory pathway of T cell activation may also render the T cells inactive in vivo. 
This can be effected by the infusion of soluble CTLA-lg (a fusion protein). It has been 
reported that lethal GVHD in the murine model can be consistently diminished 
employing these therapeutic strategies 
74
. 
Induction of suppressor cells: Several reports have suggested that some therapeutic 
manoeuvres preventing GVHD may involve the generation of suppressor cells. Sykes 
et al have shown that GVHD can be effectively prevented by treating the recipient with 
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a short course of high doses of IL-2. The underlying mechanism seems to be the 
generation of suppressor cells 75. 
GRAFT VERSUS LEUKAEMIA EFFECT (GVL) 
It was first proposed in 1956 that BM transplantation had the potential ability to 
eradicate leukaemia independently from the pretransplant radiation regime and 
chemotherapy 
76
. This effect is presently designated GVL activity. In humans, BMT is
now effectively used to cure patients with acute myelogenic leukaemia, acute 
lymphoblastic leukaemia and chronic myelogenic leukaemia n_ These beneficial effects
of BMT are often offset by the emergence of GVHD. An association between GVHD 
and GVL was recognised and reported by the Seattle BM transplant group. They 
reported that the incidence of leukaemia relapse was significantly decreased in those 
patients in whom acute or chronic GVHD supervened compared to those patients in 




. This was supported by the observation that leukaemia
relapse was more common after autologous or syngeneic BMT as documented by the 
International Bone Marrow Registry 79. 
Antitumour effector mechanisms: 
T cell mediated mechanisms: This mechanism is antigen specific, MHC restricted 
and the most potent mechanism described to date n - 81. This is best observed in MHC
mismatched situations. Both subsets of T cells have been shown to participate in the 
GVL effect. The Th2 subset has been shown to augment the GVL effect whilst it has 
been suggested that the Th1 subset is mainly responsible for the GVHD effects. 
However, there is controversy regarding the splitting of the effects and laboratory 
17 
results have demonstrated that the effects are intimately related to the strain 
combinations as well as tumour models employed 
82• 
Natural Killer (NK} and LAK cells: In contrast to T cells, NK cells can mediate a 
response without prior activation and without MHC restriction. This effect may be 
potentiated by cytokines such as IL-2. The role of these cells have been reported. NK 
cells are cells that respond most rapidly following BMT. Once activated by cytokines, 
they are called LAK cells and have a strong potential to eradicate or suppress tumour 
growth 83• 
Cytokines: Many cytokines are able to enhance the GVL effects directly or indirectly. 
Amongst these, IL-2 is thought to be the most important. It enhances the antileukaemic 
ability of both T cells and NK cells. TNFa and IFN can increase NK cell activity directly. 
Additionally, the NK cell sensitivity for low levels of IL-2 can be augmented in the 
presence of TNFa and IL-1. In addition to the above, macrophages and inflammatory 
products are also reported to play a role 84.
Disassociation of GVL and GVHO: There are various clinical and experimental 
reports suggesting that GVL effects are at least partially separable from GVHD and that 




. Patients with AML
receiving TCD allogeneic BMT showed lower relapse rates than patients receiving 
syngeneic BMT although both groups were free from GVHD implying an allogeneic 
GVL effect in the absence of GVHD 79. In an animal model, it was demonstrated that a
short course of IL-2 could inhibit GVHD with the preservation of a GVL effect 
81. 
Target cells for the GVL activity: It is possible that some minor antigens may act as 
targets for both GVHD and the GVL effect. If the GVL effect is a separate entity, it may 
18 
be concluded that there are tumour specific antigen determinants. A fusion protein 
known as p210 BCR-ABL is considered to be such a leukaemic specific antigen against 
which a class II restricted T cell response can be generated 85. Hence, these 





MATERIALS AND METHODS 
Mice: 
The following strains of mice were used in these experiments. BALB/C (H-2d, Thy1 .2+, 
Mls1 b/2a), C3H (H-2k, Thy1 .2+, Mls1 b/2a) were purchased from Charles River, 
Sulzfield, Germany. AKR mice (H-2k, Thy1 .1 +, Mls1a/2b) were obtained from 
Bomholtgard Breeding Centre Ltd., Ry, Denmark. The recipients were housed in 
groups of 6 - 10 mice per cage under filter caps with twice weekly cage changes. The 
animals were kept in solid bottom plastic cages with a plastic top fitted with a filter. 
Standardised pellet chow and acidified drinking water were used as routine. Antibiotic 
(Tylan, Eli Lilly, Brussels, Belgium) was added to the drinking water one week before, 
during and one week after BMT. 
Induction of chimaerism 
• Irradiation
Recipient mice received either 9.5 Gy or 10.5 Gy of Total Body Irradiation (TBI) as a 
single dose or Total Lymphoid Irradiation (TLI) = {10 TLI + 2 TBI, each fraction 
consisting of 2 Gy as a daily fraction}. The irradiation was delivered by a 60 Cobalt 
source at a dose rate of approximately 0.3 Gy/min. The source to skin distance was 
approximately 100cm for the TBI group and 80cm for the TU group. During TLI, the 
skull, lungs, kidneys, tail and long bones of the animals were shielded with lead blocks 
thus exposing the supra- and infradiaphragmatic lymph nodes, spleen and thymus to 
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the irradiation field. Shieldings were focal and made of MCP. Before TLI, all mice were 
placed in a prone position and after being induced with enflurane, anaesthesia was 
then maintained using Enflurane delivered and controlled by a semi-closed circuit 
inhalation system. TBI groups were irradiated without anaesthesia. Six mice were 
irradiated at a time. 
• Preparation of chimaeras
One day after irradiation, the recipients were reconstituted with bone marrow cells. TBI 
mice were reconstituted with either T cell depleted allogeneic bone marrow cells ( 5 x 
106 cells) or T cell depleted syngeneic BMT ( 5 x 106 cells) + non T cell depleted 
allogeneic bone marrow cells (15 x 106 cells) to circumvent the complication of GVHD. 
T cell depletion was carried out in vitro using monoclonal antibodies and low toxic 
rabbit complement. 
TLI groups were reconstituted with non T cell depleted allogeneic BMT (15 - 30 x 106 
cells). 
Bone marrow cells were prepared by flushing the shafts of donor animal's femora and 
tibia (6 - 8 weeks old) using heparinised RPMI 1640R with Glutamine and antibiotics. 
The cells were washed twice with RPMI, counted and suspended in 0.3ml ice cold 
RPMI and injected into the recipient via the tail vein. 
• Scoring of Chimaerism
Scoring of chimaerism was performed by using a flow cytometric assay that had been 
previously demonstrated to identify chimaerism as low as 2%. Chimaerism was 
confirmed in the live animals with the use of monoclonal antibodies conjugated with 
phtcoerythrin (PE) and flouresceinated isothiocyanate (FITC) after aspirating 0.2 ml of 
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blood from the heart under anaesthesia. This confirmation was undertaken after the 
animals had regained the pre-irradiation weight and were clinically well and 
demonstrated no evidence of GVHD to confirm Engraftment in the absence of GVHD. 
• Determination of Vb6
+ 
cells
This was determined by double colour FACS analysis after confirmation of engraftment 
as well as clinical confirmation of the absence of GVHD. 
IN VITRO ASSAYS 
• Mixed Lymphocyte Reaction (MLR)
The MLR is an in vitro proliferative response of T cells to allogeneic cell associated 
antigens. It was performed by culturing responder cells with allogeneic stimulator cells 
(irradiated) together in a medium at a concentration of 5 x 106 cells/ml and at a final 
volume of 200µ1 per well in 96 well flat bottomed microculture plates. The MLR medium 
was prepared with RPMI 1640 with glutamine with added antibiotics and 10% foetal calf 
serum (FCS). 5 x 1 o-5M 2-mercaptoethanol was added. The stimulator cells were 
prepared by irradiating them with 3000 rads. Cells were cultured in quadruplicate and 
were always accompanied by negative controls (i.e. wells with responder cells alone 
and with stimulator cells alone). The cultures were incubated for 96 hours at 37°C in a 
5% CO2 humidified incubator. DNA synthesis was assayed by the addition of 1 µCi 
[methyl-3h] thymidine per well and incubated for an additional 18 hours. Thereafter, the 
cells were harvested onto glass filter paper and the counts per minute (cpm) 
determined in a liquid scintillation counter. The Stimulation Index (SI) was used to 
assess the MLR. It was calculated as follows: 
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SI = cpm of stimulated cells - cpm of unstimulated cells 
cpm of unstimulated cells 
NK/LAK CYTOTOXIC ASSAYS 
Standard Chromium release assays were used to determine NK/LAK cell activity. YAC-
1 and BW-5147.3 (AKR mouse lymphoma) tumour cells were used as targets for NK 
and LAK cell mediated cytotoxic activity respectively. After 2 washes with RPMI 1640, 
1x10
6 
target cells were resuspended in 0.4 ml of media containing RPMI + 5% FCS. 
The cells were then labelled with 200µci 
5
Cr in loosely capped 15 ml conical tubes and 
were incubated at 37°C for 90 min in a 5% CO2 incubator. Thereafter, the 
51
Cr labelled 
target cells were washed 3 times with RPMI. The cells were resuspended in RPMI + 
10%FCS and were adjusted to a concentration of 1x10
5 





/well) were mixed 
51
Cr labelled target cells in a final volume of 0.2 ml 
per well (quadruplicate) in 96 well V bottom microtitre plates at an effector: target ratio 
of 50: 1. The cells were incubated in a 5% CO2 incubator for 4 hours at 37
°C. 
Thereafter, the plate was centrifuged for 2 minutes and 100 µI of supernatant was 
collected into counting vials and counted in a Gamma counter. Cell lysis was evaluated 
by measuring the amount of radioactivity released into the supernatant. 
The percentage specific lysis was measured using the following formula: 
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%age lysis = mean cpm of experimental release - mean cpm of spontaneous release 
mean cpm of maximal release - mean cpm of spontaneous release 
Spontaneous release was determined by incubating target cells in medium only and the 
maximum release was determined by incubating the target cells with detergent 
(saponine). LAK cells were generated by incubating single cell suspensions harvested 
from the spleens of the relevant sacrificed mice and incubating them in medium 
consisting of RPMI 1640 + antibiotics, 10% FCS, and 5x10·5 2-mercaptoethanol. 1Ox106 
cells were cultured in a single flask at a concentration of 2x106 cells/ml of medium in 
the presence of mouse IL-2 [1000 U/ml] for 4 days in a 5% CO2 incubator at 37
°C. Cells 
were then washed and adjusted to the appropriate concentration. 
Suppressor Cell Assays 
Culture conditions were the same as for the MLR except that 5x105 putative suppressor 
cells (irradiated with 15 Gy) were cocultured with responder and stimulator cells in a 
final volume of 0.3 ml/well for 120 hours before pulsing with thymidine. 
Preparation of Polyclonal Antisera 
Donor mice were anaesthetised with ether. The abdominal skin was scrubbed with 70% 
alcohol. Full thickness skin of approximately 1 cm2 was excised and preserved 
immediately in ice cold PBS. Recipient mice were anaesthetised with ether. The hair 
was shaved off the flank. A 1 cm2 area of skin was excised and the donor skin was 
engrafted and held in place with the placement of silk sutures. The grafted area was 
dressed with paraffin gauze, gauze, and plaster of paris. After 7 days, the bandages 
were removed to confirm engraftment and monitor for graft rejection. Once rejection 
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was observed, the recipients were immunised with thrice weekly intraperitoneal 
injections of 50x106 irradiated allogeneic spleen cells in complete Freunds adjuvant 
(CFA). Ascitic fluid was collected, sterilised with filtration and purified by ammonia 
precipitation. 
Histological examination 
Histological examination of the viscera of the experimental groups were performed to 
clarify the presence of GVHD or tumour infiltration. Dead mice or sacrificed mice were 
dissected and specimens taken were the heart, lungs, liver, spleen, small bowel, large 
bowel, pancreas, bone marrow and brain. Harvested specimens were kept in Bouins 
medium for a week, thereafter, the specimens were dehydrated and then sectioned and 
stained. 
Induction of GVHD 
GVHD was induced to assess in vivo the T cell reactivity against major or minor 
histocompatible antigens. The following protocols were used to induce GVHD: 
A single spleen cell suspension was prepared in MEM. 40 x 106 in 0.3 ml medium was 
used to induce GVHD. The cells were injected intravenously through the lateral tail vein 
that was distended using an heating lamp. The following criteria were used for the 
evaluation of GVHD 
• Clinically: weight loss, hunched back, diarrhoea and alopecia
• By monitoring the survival curves




• Liver: mononuclear cell infiltrate in the peripheral zone
• Spleen: depletion of lymphocytes in the white pulp and the loss of germinal
centers
• Lymph nodes: aplasia of lymph nodes and absence of germinal centres and
proliferation of lymphoid cells in the paracortical zone
• Skin and intestines: mononuclear cell infiltrate
Tumour cell titration assay 
To determine the number of AKR tumour cells needed to cause lethal tumour 
development in AKR mice, BW 5147.3 tumour cells in MEM were injected intravenously 
into control mice. The mice were then observed daily for mortality. Different numbers of 
tumour cells were injected intravenously into normal control AKR, C3H and BALB/c 
mice. C3H and BALB/c mice remained healthy and never developed any tumour after 
infusion of 6 x 106 tumour cells. At the maximum dose used in this experiment, all AKR 
mice succumbed to tumour by three weeks. 
Induction of BM chimeras (MC) were constructed by infusing 15X106 C57BI/10 BM 
cells into lethally irradiated (10.5 Gy of total body irradiation) F1 recipient mice. In all 
MC, between 15% and 49% of host-type peripheral blood leukocytes were shown to 
persist after BM transplantation using a sensitive flow cytometry assay (13, 14). 
Complete chimeras (CC) were made by infusion of only 20X106 C57BL/10 BM cells. In 
CC, the presence of remaining host-type peripheral blood lymphocytes could not be 
demonstrated, despite multiple determinations. In all BM transplantation experiments, 
T cell depletion of the BM cells was achieved before infusion using anti-Thy 
monoclonal antibodies (Becton Dickinson, Mountain View, CA) and rabbit complement 
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(Cedarlane, Ontario, Canada). After BM transplantation, the animals were kept in 
specific pathogen-free conditions and were free from clinical and histological signs of 
graft-versus-host disease. 
Immunization of chimeras. Three months after BM transplantation, chimeric and 
control mice were immunized intraperitoneally once a week for 3 weeks with 50X106 
irradiated (30 Gy) host-type (BALB/c), donor-type (C57BU10), or third-party-type 
(C3H) spleen cells (four mice per group for each antigenic stimulus). Ten days later, 
splenocytes were taken for mixed lymphocyte reaction (MLR) tests performed with 
immunizing cells as stimulator cells; sera were analyzed for the presence of antibodies 
directed against the immunizing cells. 
Detection of lgG alloantibody formation. Alloantibody detection was performed 
using a modification of the flow cytometry crossmatch technique, as we described 
previously (14). Briefly, 1X106 target spleen cells in 0.1 ml of saline solution were 
Incubated with 0.1 ml of various dilutions of serum from non-immunized and immunized 
mice. Thereafter, the cells were washed and incubated for an additional 20 min with 
0.1 ml of various dilution of serum from non-immunized and immunized mice. 
Thereafter, the cells were washed and incubated with 15 ul of Fluorescein 
lsothiocyanate-conjugated goat antimouse1gG Fe (The Binding Site, Birmingham, 
England) for 20 min. This second step detects only mouse 1 gG and hence does not 
stain mouse B cells as only a negligible fraction of them express 1gG in mice. Serum 
titers were scored positive when they showed a significant shift in the mean fluorescein 
intensity by flow cytometry (FACScan, Becton Dickinson). 
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Detection of alloantibodies directed against MHC class I or class II expressing 
cells. Because murine T lymphocytes express only MHC class I antigens and not MHC 
class II antigens, anti-MHC class I-directed antibodies were assayed by two-color flow 
cytometry using anti-L3T4 (Becton Dickinson) Phycoerythrin-coupled monoclonal 
antibody (directed against the murine CD4
+ 
T lymphocyte subset) and Flourescein 
lsothiocyanate-conjugated anti-mouse lgG (Fe) monoclonal antibody. For assaying 
reactivity on class II-expressing cells, relevant anti-MHC class II-reacting anti-I-A
b
, -I-Ad
biotin-conjugated antibodies (PharMingen, San Diego, CA) were used. 
Purification of T and B lymphocytes. T lymphocytes and B lymphocytes were 
purified from splenocyte suspensions using a panning technique. Rabbit anti-mouse 
1 g was first diluted to 10 ul per 10 ml of phosphate-buffered saline (PBS). 
Petri dishes (Falcon, Becton Dickinson, Belgium) were coated with 10 ml of this 
solution and kept at 4° C overnight. The following morning, the solution was poured off
and the Petri dishes washed three times with PBS. A single suspension of spleen cells 
was prepared in RPMI medium containing 10% fetal calf serum plus antibiotics. Six 
milliliters of medium containing 100X10
6 cells were added to each Petri dish and kept 
for 30 min at room temperature. Thereafter, the Petri dishes were rotated for 30 sec. 
To isolate the T cell population, non-adherent cells were poured into a second 
antibody-coated Petri dish and kept for another 30 min at room temperature. 
Thereafter, the non-adherent cells were collected into a tube. To isolate the B cell­
enriched populations, the Petri dishes containing the adherent B cells were first 
washed three times with sterile PBS to remove remaining T cells. Thereafter, 5 ml of 
culture medium containing 10% normal mouse serum were added and incubated at 37° 
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C for 1 hr in order to selectively dislodge the adherent B cells. B cells were then 
collected by pipetting into a tube and were washed two times with RPMI. This panning 
technique resulted in highly purified populations (>95% purity) of T and B lymphocytes. 
Where necessary, purification of donor lymphocytes from MC was done subsequently 
using C57BL anti-BALB/c alloantibodies and rabbit complement. After this procedure, 
no remaining BALB/c cells could be detected by flow cytometry. 
Transfer experiments. For the transfer experiments, lethally irradiated (12 Gy) control 
C57BL/10 mice were given 15X106 purified T cells and 15X106 purified B cells 
intravenously from various origins. One week later, the mice were immunized 
intraperitoneally once a week for 2 weeks with 1X108 irradiated (30 Gy) BALB/c or C3H 
spleen cells. A week after this, the serum was taken for alloantibody detection. 
Alloantibodies were scored using flow cytometry as described above. 
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CHAPTER4 
MECHANISMS UNDERLYING TRANSPLANTATION TOLERANCE IN 
MIXED BONE MARROW CHIMERAS IN A SEMIALLOGENEIC 
COMBINATION INDEPENDENT OF GRAFT VERSUS HOST DISEASE 
INTRODUCTION 
Bone Marrow Transplantation (BMT) is now an established procedure in clinical 
medicine. It has been successfully used to salvage patients from intensive cytoablative 
therapy especially for haematological malignancies. This success, especially with 
successful allograft transplantation, has alerted clinicians to the application of this form 
of therapy for a more diverse group of conditions such as immunodeficiencies, 
metabolic deficiencies, auto-immune disorders, benign haematological disorders, 
genetic abnormalities and the most recent, inducing donor specific tolerance. In 
addition, oncologists are now exploring the potential of BMT to salvage patients with 
solid tumours following more intensive cytoablative therapy. 
These potential applications have not been universally adopted in clinical practice 
because BMT is fraught with problems. The most sinister complications limiting the use 
of BMT are Engraftment failure, the ravages of the conditioning regime, Graft Versus 
Host Disease (GVHD), and Graft Rejection. The literature attests to the magnitude and 
prevalence of these problems. The lack of alternative, consistently successful therapy 
for these conditions has prompted research into BMT to enable a more liberal clinical 
application. 
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Whilst immunosuppressive therapy has evolved to become more precise, optimum 
conditioning regimens, quality of the Bone Marrow Transplant and the mechanisms of 
Engraftment and GVHD need to be determined to allow clinicians greater access to this 
therapy. 
AIMS 
This study was undertaken to 
1. Attempt to establish the mechanisms sustaining transplantation tolerance in a
semiallogeneic murine model using different conditioning regimens with the
elimination of GVHD
2. To determine the immunocompetence of the different regimens
MATERIALS AND METHODS 
Mice: 6 - 12 week old mice were purchased. C3H/HeJ (H-2k, Thy 1.2, Mis 1 b/2a) and 
Balb/c (H-2d, Thy 1.1, Mis 1 b/2a) were purchased from Charles River (Sulzfield, 
Germany) and AKR/J (H-2k, Thy 1.2, Mis 1 a/2b) were purchased from Bomholtgard 
Breeding Center Ltd. (Ry, Denmark) 
Recipient mice were housed in plastic cages fitted with a filter cap, had sawdust 
bedding and housed in a pathogen free environment. Pellet chow and acidified drinking 
water was the standard diet. Antibiotic (Tylan, Eli Lilly, Brussels, Belgium) was added to 
the drinking water 1 week prior to BMT and was continued for a week following it. 
Irradiation: Recipient mice received either 9.5 Gy Total Body Irradiation (TBI) as a 
single dose or Total Lymphoid Irradiation (TLI) as 12 daily fractions (10 TLI + 2 TBI) of 
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2 Gy each as described previously. Irradiation was delivered by a 60 Cobalt source 
(Gammatron, Siemens) at a low dose rate. The source to skin distance for the TBI was 
100 cm and for mice receiving TLI, the distance was 80 cm. Mice receiving TLI were 
anaesthetised; they were induced with enflurane and then maintained on anaesthesia 
in a prone position using Enflurane (Abbott, s.p.a., Campoverde-LT, Italy) delivered by 
a semi-closed inhalation anaesthetic system. The skull, long bones, kidneys, lungs and 
tail were shielded with lead blocks confining irradiation to the thymus, spleen, supra­
and infradiaphragmatic lymph nodes. A maximum of 6 mice were irradiated 
simultaneously. 
BMT: To prepare stable mixed chimeras with the elimination of GVHD, the recipient 
mice were reconstituted with donor cells in the following manner: 
TBI chimeras were prepared with 5 x 106 T cell depleted (TCD) allogeneic bone 
marrow. TCD was performed in vitro using Thy 1.1 (Serotech, Oxford, UK) or Thy 1.2 
(Sigma Chemie, GmbH, Drisenhof, Germany) antibodies and low toxic rabbit 
complement (Cedarlane, Hornby, Ontario, Canada). 
TLI chimeras were prepared with 15 x 106 non-TCD allogeneic bone marrow. 
Bone marrow cells were harvested by flushing the shafts of the sacrificed donor 
animals with a solution of RPMI with antibiotics and 1 % heparin. The cells were washed 
twice with RPMI with added antibiotics. The viable cell count was determined by 
staining with Trypan blue and counted in a Burker haemocytometer. Cells were kept on 
ice throughout. The cells were reconstituted to the relevant concentration such that 
0.25 ml was injected into the tail vein of the recipient, with the appropriate number of 
cells. 
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Determination of chimerism and Vp6cells 
Chimerism was determined in a Flourescein Activated Cell Sorter (FACS) assay using 
Thy 1.1 (Serotech, Oxford, UK), and Thy 1.2 (Sigma Chemie, GmbH, Drisenhof, 
Germany) monoclonal antibodies (mAbs) conjugated with Phycoerythrin (PE) and 
Flourescein lsothiocyanate (FITC) respectively. These are lymphocyte markers 
specifically confined to either donor cells or recipient cells depending on the direction 
of the transplantation. 
Vp6 cells were evaluated in the CD4 window (Caltag lab, San Francisco) with Vp6 mAb 
(Pharmingen, Antwerp, Belgium) and percentages were estimated in the peripheral 
blood lymphocytes, thymus, splenic lymphocytes and lymph node lymphocytes. 
Mixed Lymphocyte Cultures (MLC): 
Responder cells: Single cell suspensions were made from the spleen/s of the 
responder mice by teasing them into fragments with forceps in RPMI on ice and then 
passed through a 100 µm cell strainer and washed twice with RPMI with added 
antibiotics. The viable cell count was determined. The cells (maximum of 108 cells) 
were incubated at 37
°C in a 5% CO2 incubator in 2 ml of RPMI with 5% foetal calf 
serum (FCS) in a nylon wool syringe. This syringe was previously washed with 50 ml 
of the same solution and kept in the incubator for a minimum of 1 hour prior to use. The 
enriched T cells were eluted. This was done by simply washing the non-adherent T 
cells from the syringe by passing 20 ml of the medium through the syringe and 
collecting the fluid under sterile conditions. The eluted cells were counted and made up 
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to a concentration of 5 x 106 cells/ml in RPMI with 10% FCS and 2ME 
(Mercaptoethanol). 
Stimulator cells: Single cell suspensions were prepared from the spleen/s of the mice 
as described as above. The cells were counted and made up to a concentration of 5 x 
106 cells/ml in RPMI with 10% FCS and 2ME. These cells were irradiated with 3000 
Rads and kept in the incubator until use. 
Chimeric cells: Cells of donor or recipient origin form the chimeric animals were 
isolated from single spleen cell suspensions by incubating the spleen cells with 
polyclonal antibodies* in RPMI with 20% FCS. After incubation, the cells were washed 
twice with RPMI to remove excess unbound antibodies and the cells were then 
incubated with low toxic rabbit complement for 45 minutes in a 37°C water bath. The 
cells were washed twice with RPMI. Cell counts were determined and the cells were 
reconstituted to yield a concentration of 2,5 x 106 cells/ml in RPMI with 10% FCS and 
2ME. These cells were irradiated with 1500 Rads and were added to the MLC to 
determine their influence on it. 
Vp6cells: These cells were isolated from single cell suspensions from the thymus of 
chimeric AKR mice using magnetic beads to isolate the cells and then bringing them to 
a concentration of 2.5 x 106 cells/ml. 
The cells were plated into 96 well flat bottom plates; 5 x 105 responder cells and 5 x 105 
stimulator cells were added to the wells in the experiments. Four experiment wells were 
performed and the mean values were used. Chimeric cells were added i.e. either of 
donor or recipient origin to determine their influence on this reaction, again performed 
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in 4 wells and the mean value taken. Control wells comprised cells from each group 
without the addition of other cells. 
The cells were incubated for a period of 96 hours in an incubator. Thereafter, 10:1 of 
[H1 Thymidine was added to each well and the cells were incubated for an additional 
16 hours after which the cells were harvested and the radioactivity measured. Results 
were interpreted as the mean of the experimental counts minus the sum of the mean 
counts of the relevant control cells. 
Polyclonal antisera: Polyclonal antibodies were raised by skin grafting the mice with 
skin from the allogeneic mice against which antibodies were to be raised. Once 
rejection occurred, the grafted mice were injected repeatedly with 5 x 106 donor 
haematopoeitic cells in Complete Freunds Adjuvant intraperitoneally until the 
development of ascites. The ascites was harvested, centrifuged, filtered by passage 
through a 1 00µm filter and stored at -20°C. The concentration of the antibodies 
necessary was established by titration against a known concentration of cells. 
Cotransfer experiments 
Recipient mice were lethally irradiated (10,5 Gy) and injected with 40 x 106 splenocytes 
of donor origin and simultaneously with tolerant splenocytes of either donor or recipient 
origin from the chimeric animals also at a dose of 40 x 106 cells. The 5 groups were: 
Group 1: Donor splenocytes alone 
Group 2: Donor splenocytes + Chimeric TBI donor splenocytes 
Group 3: Donor splenocytes + Chimeric TBI recipient splenocytes 
Group 4: Donor splenocytes + Chimeric TU donor splenocytes 
Group 5: Donor splenocytes + Chimeric TU recipient splenocytes 
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RESULTS 
RESPONSE TO IRRADIATION AND TRANSPLANTATION 
All mice subjected to the conditioning regimens lost significant weight following 
irradiation and transplantation. However, this was regained to pretransplant 
conditioning levels by the end of the second week confirming the absence of GVHD. 
CHIMER/SM 
All mice subjected to BMT were confirmed via a Flouresceinated Activated Cell Sorter 
(FACS) assay performed on blood taken from direct cardiac puncture after the mice 
were anaesthetised with ether. The extent of the chimerism was a mean of 52% (44 -
60) in the TBI group and a mean of 46% (30 - 52) in the TU group. All mice were
healthy; they displayed no features of GVHD such as alopecia, hunched back or 
diarrhoea. The weight loss imparted by the conditioning regime was rapidly recruited 
following BMT by the end of 2 weeks. 
CLONAL DELETION 
Vp6 cells normally comprise 9 - 11 % of the CD4 population of the lymphocytes of C3H 
mice and are absent in AKR mice. They are normally reactive to the Mis antigen 
present in the AKR mice. This allowed for the Vp6 cells to be evaluated in the separate 
models to determine whether clonal deletion played a role in this model of 
transplantation tolerance. 
In the TU mice, Vp6 cells were deleted in both groups; i.e. they were not evident in the 
C3H mice who received AKR bone marrow and were not present in the AKR mice when 
these had received C3H marrow. This confirms that clonal deletion is an important 
mechanism underlying transplantation tolerance when TU is used as a conditioning 
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regime and deletion occurs in both the donor marrow as well as in the recipient that is 
reactive to the donor cells. 
When C3H marrow was transplanted into AKR mice conditioned with TBI, clonal 
deletion of VJ36 cells was demonstrated. However, these mice were transplanted with 
TCD bone marrow and this may reflect the inability of the immature cells of donor origin 
to proliferate into mature T cells thereby facilitating their deletion by host cells since 
they are reactive to host cells. This also suggests that clonal deletion is one of the 
mechanisms sustaining transplantation tolerance in this model after conditioning with 
TBI. 
In sharp contrast to the phenomenon seen in the previous groups, C3H mice 
transplanted with TCD bone marrow of AKR origin following TBI show a proliferation of 
VJ36 cells. This was evident in all compartments i.e. they were present in increased 
percentages in the peripheral blood, thymus, spleen and lymph nodes (Table 1 &2). The 
significance of this cell proliferation was determined in the in vitro assays. 
Table 1 
TYPE OF CHIMAERA VJ36 cells 
C3H (BM) into AKR (TBI) TCD DELETED (0%) 
C3H (BM) into AKR (TLI) NTCD DELETED (0%) 
AKR (BM) into C3H (TBI) TCD PROLIFERATION 
AKR (BM) into C3H (TLI) NTCD DELETED(0%) 
Presence of VJ36 cells in chimaeras 
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Table 2 
Animal 1 Animal 2 Animal 3 Animal 4 Animal 5 
PBL 22 36 35 36 20 
Lymph node 6 5 11 16 17 
spleen 26 19 25 26 26 
thymus 34 44 50 33 21 
Percentage of V�6 cells in TBI chimaeras 
IN VITRO ASSAYS 
Confirmation of tolerance: 
MLC done with responder cells from the chimeric animal spleen cells against irradiated 
spleen cells of na'ive donor and recipient animals confirmed that no proliferative 
response was generated. This confirmed that transplantation tolerance was achieved. 
To establish that this did not reflect an immunosuppressive state, the chimeric cells 
were used as responder cells against third party antigens. Irradiated Balb/c 
splenocytes were used as stimulator cells and both the TU chimeras as well as the TBI 
chimeras achieved significant proliferative responses against these antigens (Fig 1 ). 
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Fig. 1 
EVALUATION OF CHIMAERIC CELLS AGAINST NAIVE 
DONOR, HOST AND THIRD PARTY CELLS 
� 60 
� 50 
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TBI-AKR TBI-C3H TLI-AKR TLI-C3H 
Test StatisticS"·b 
TBIAKR TBIC3H TLIAKR TLILBH 
Chi-Square 9.846 9.846 9.846 9.846 
df 2 2 2 2 
Asymp. Sig. .007 .007 .007 .007 
a. Kruskal Wallis Test
b. Grouping Variable: STRAIN
Descriptive Statistics - For Strain AKR 
Std. 
N Minimum Maximum Mean Deviation 
TBIAKR 4 932.00 1055.00 994.0000 50.2195 
TBIC3H 4 3978.00 4052.00 4004.5000 34.2394 
TLIAKR 4 807.00 992.00 867.7500 83.9697 
TLILBH 4 2809.00 3211.00 3002.2500 168.8735 
Valid N (listwise) 4 
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Descriptive Statistics - For Strain C3H 
Std. 
N Minimum Maximum Mean Deviation 
TBIAKR 4 2824.00 3397.00 3147.2500 241.2238 
TBIC3H 4 942.00 1102.00 1015.2500 77.6375 
TLIAKR 4 1876.00 2234.00 2040.2500 171.7525 
TLILBH 4 914.00 1067.00 977.5000 68.8985 
Valid N (listwise) 4 
Descriptive Statistics - For Strain BALB / C 
Std. 
N Minimum Maximum Mean Deviation 
TBIAKR 4 47550.00 48980.00 48115.00 614.9526 
TBIC3H 4 47459.00 48242.00 47828.25 406.5287 
TLIAKR 4 33914.00 34082.00 33998.75 80.0307 
TLILBH 4 35807.00 36163.00 36007.00 148.2700 
Valid N (listwise) 4 
Evaluation of the influence of the chimeric cells on the MLC of naive donor and 
recipient splenocytes 
When spleen cells from narve donor animals were used in a MLC against na·ive 
recipient cells or vice-versa, a good proliferative response was attained. However, the 
addition of cells of either donor or recipient origin from the TBI chimeras resulted in a 
significant depression in the response. This is suggestive of a suppressive mechanism 
also responsible for sustaining transplantation tolerance. To establish that this was 
specific to the mechanisms sustaining tolerance, these cells were added to a MLC 
against third party antigens (Balb/c splenocytes). This did not result in an abrogation of 





N Minimum Maximum . Mean Deviation 
C3H 4 49886.00 50047.00 49975.00 72.8331 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 10947.00 11107.00 11019.00 70.0904 
Valid N (listwise) 4 
Ranks 
Mean Sum of 
STRAIN N Rank Ranks 
C3H 3.00 4 6.50 26.00 




Mann-Whitney U .000 
Wilcoxon W 10.000 
z -2.309
Asymp. Sig. (2-tailed) .021
Exact Sig. [2*(1-tailed a 
Sig.)) .029 
a. Not corrected for ties.
b. Grouping Variable: STRAIN
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 61977.00 62107.00 62035.50 56.2761 
AKR 4 66487.00 66600.00 66553.25 50.2154 




N Minimum Maximum Mean Deviation 
C3H 4 54400.00 54800.00 54664.75 180.6237 
AKR 4 59750.00 59837.00 59788.00 38.8072 
Valid N (listwise) 4 
Ranks 
Mean Sum of 
STRAIN N Rank Ranks 
C3H 5.00 4 6.50 26.00 
6.00 4 2.50 10.00 
Total 8 
AKR 5.00 4 6.50 26.00 




Mann-Whitney U .000 .000 
Wilcoxon W 10.000 10.000 
z -2.309 -2.309
Asymp. Sig. (2-tailed) .021 .021
Exact Sig. [2*(1-tailed a a 
Sig.)] 
.029 .029 
a. Not corrected for ties.
b. Grouping Variable: STRAIN
When this experiment was performed using cells of either donor or recipient origin from 
the TLI chimeras the response was increased. This may be explained on the basis of 
better antigen presentation when the added cells are responder cells in origin or, on 
the basis of a greater volume of antigen if the added cells are of stimulator origin. This 
suggests that suppression is unlikely to play a role in the transplantation tolerance. 
Furthermore, tolerance is unlikely to be based on the presence of veto or suppressor 
cells as suggested by this MLC result (fig. 3). 
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Fig. 3 
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Ranks 
Mean 
STRAIN N Rank 
AKR 1.00 4 2.50 




Mann-Whitney U .000 
Wilcoxon W 10.000 
z -2.309
Asymp. Sig. (2-tailed) .021






N Minimum Maximum 
AKR 4 56100.00 56247.00 
















N Minimum Maximum Mean Deviation 
AKR 4 58547.00 58696.00 58623.50 63.3535 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 50979.00 51104.00 51044.75 51.5841 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 57768.00 57971.00 57874.25 83.1560 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 50979.00 51104.00 51044.75 51.5841 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 57768.00 57971.00 57874.25 83.1560 
Valid N (listwise) 4 
Test Statistics' 
C3H 
Mann-Whitney U .000 
Wilcoxon W 10.000 
z -2.309
Asymp. Sig. (2-tailed) .021
Exact Sig. (2*(1-tailed a 
Sig.)) 
.029 
a. Not corrected for ties.




N Minimum Maximum Mean Deviation 
AKR 4 60440.00 60583.00 60492.50 66.0126 
C3H 4 60729.00 60850.00 60798.50 50.5602 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
AKR 4 61700.00 61809.00 61750.25 48.5481 
C3H 4 62107.00 62494.00 62345.75 171.7389 
Valid N (listwise) 4 
Test Statistics> 
C3H AKR 
Mann-Whitney U .000 .000 
Wilcoxon W 10.000 10.000 
z -2.309 -2.309
Asymp. Sig. (2-tailed) .021 .021
Exact Sig. [2*(1-tailed a a 
Sig.)) .029 .029 
a. Not corrected for ties.
b. Grouping Variable: STRAIN
To establish the significance of the Vp6 cells that were expanded in the TBI chimeras, 
single positive (CD4) Vp6 cells were added to the na'ive response. These cells resulted 
in a significant depression of the response irrespective whether the responder cells 
were of donor or recipient origin. This suppression was found to be non-specific as it 
abrogated the response even when third party antigens were used (fig. 4) 
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Fig. 4 
INFLUENCE OF Vb6 CELLS ON MLC 
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Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
AKR 4 50847.00 51107.00 50973.25 108.5798 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
AKR 4 443.00 643.00 558.2500 86.2839 
Valid N (listwise) 4 
Ranks 
Mean Sum of 
STRAIN N Rank Ranks 
AKR 1.00 4 6.50 26.00 





Mann-Whitney U .000 
Wilcoxon W 10.000 
z -2.309
Asymp. Sig. (2-tailed) .021
Exact Sig. [2*(1-tailed a 
Sig.)] 
.029
a. Not corrected for ties.
b. Grouping Variable: STRAIN
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 51846.00 52110.00 52003.50 127.4088 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 779.00 954.00 883.5000 74.1463 
Valid N (listwise) 4 
Ranks 
Mean Sum of 
STRAIN N Rank Ranks 
C3H 3.00 4 6.50 26.00 




Mann-Whitney U .000 
Wilcoxon W 10.000 
z -2.309
Asymp. Sig. (2-tailed) .021
Exact Sig. [2*(1-tailed a 
Sig.)] 
.029
a. Not corrected for ties.




N Minimum Maximum Mean Deviation 
C3H 4 53097.00 53400.00 53202.25 139.4426 
AKR 4 51400.00 51797.00 51569.25 173.6076 
Valid N (listwise) 4 
Descriptive Statistics 
Std. 
N Minimum Maximum Mean Deviation 
C3H 4 1350.00 1566.00 1458.0000 94.6150 
AKR 4 846.00 1004.00 947.5000 72.9498 
Valid N (listwise) 4 
Ranks 
Mean Sum of 
STRAIN N Rank Ranks 
C3H 5.00 4 6.50 26.00 
6.00 4 2.50 10.00 
Total 8 
AKR 5.00 4 6.50 26.00 




Mann-Whitney U .000 .000 
Wilcoxon W 10.000 10.000 
z -2.309 -2.309
Asymp. Sig. (2-tailed) .021 .021
Exact Sig. [2*(1-tailed a a 
Sig.)] .029 .029 
a. Not corrected for ties.
b. Grouping Variable: STRAIN
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INFLUENCE OF ALLOGENEIC TUMOUR INNOCULATION 
The suppressive response demonstrated in vitro by both the host and donor cells from 
the chimeric TBI chimeras was unexpected. This strongly challenged the widely held 
view that mixed chimeras have a superior immunocompetence to either donor or 
recipient individually. To establish the magnitude of this suppression, C3H TBI 
recipients confirmed to be chimeric and healthy were injected with tumour cells BW 
5147.3. These cells are from a lymphoma/ leukaemia AKR line. Normally, this tumour 
innoculation has no deleterious effects on C3H mice. However, in the TBI mice of C3H 
origin reconstituted to mixed chimeras with AKR/J bone marrow, all the mice 
succumbed to tumour innoculation by 22 days (fig. 5). Two phenomena that were 
recognised in this experiment were engraftment and susceptibility. 
Fig. 5 
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COTRANSFER OF TOLERANT CELLS - EVIDENCE FOR CELLS PROTECTIVE
AGAINST GVHD 
In the cotransfer experiments, 40 x 106 cells of narve donor origin were injected into the 
lateral tail vein veins of lethally irradiated recipient mice. Simultaneously, splenocytes 
from the tolerant chimeras were injected intravenously as well and, were either of donor 
or host origin to determine the source of the cells maintaining transplantation tolerance. 
As anticipated, those mice injected with narve splenocytes alone succumbed to lethal 
GVHD within 3 weeks of reconstitution. 
In the TBI cotransfer groups, both the tolerant donor cells and the tolerant recipient 
cells conferred protection against the emergence of lethal GVHD. These mice remained 
healthy at the 2month and 5month evaluation period (fig.6). This was most likely due to 
the suppressive nature of these cells as evident in the in vitro experiments. 
Fig. 6 
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In the TLI group, the co-injection of tolerant donor cells conferred no significant benefit 
to the outcome of these mice except that there was a marginal prolongation in survival 
with the longest survivor demising at 34 days. 
In contrast, cells of recipient origin unexpectedly circumvented the onset of GVHD but 
the mechanism underlying this protection is not readily apparent in this study and this 
protection persisted when chimeric tolerant cells from TLI chimeras were co-injected 
(fig 7). This would require further evaluation in subsequent studies. The suggestion 
from the cotransfer experiments is that, beyond clonal deletion, recipient cells also play 
an active role in either deleting or suppressing donor reactive cells. 
Fig. 7 
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The attainment of mixed chimerism with BMT is attractive owing to the theoretical 
potential of superior immunocompetence. There is consensus that for BMT to become 
more widely adopted, engraftment success must be more predictable together with the 
elimination of GVHD. Clinicians have attempted to achieve this by either increasing the 
lethality of the conditioning regime, increasing the immunosuppressive regime, the use 
of more specific immunosuppressive agents and the manipulation of the BMT by either 
T cell depletion or the transfusion of pure stem cells (CD 34) cells. 
In order to identify new strategies to optimise BMT both to ensure engraftment as well 
as reduce the incidence of GVHD it is imperative that the mechanisms sustaining 
transplantation tolerance be predictable. At present, four methods have been described 
and confirmed in experimental models. These are clonal deletion, 
immunosuppressive cells, veto cells and clonal anergy. The mechanism by which 
these various strategies emerge is not predictable and at present it is postulated that 
this is determined by the quality of the BMT and the disparity in MHC. 
The results from this study have highlighted some interesting issues that need to borne 
when considering BMT as a therapeutic option. The influence of the conditioning 
regimen is well highlighted in this study. TLI as a conditioning regimen allows for 
mature T cells to be transfused without imposing the risk of GVHD. The mechanism of 
transplantation tolerance that is subsequent to this type of transplantation is based 
mainly on clonal deletion. This was borne out in the in vitro studies where the MLC was 
unresponsive to both donor and recipient cells. However, the co-transfer experiments 
suggests that another probable mechanism facilitating transplantation tolerance is the 
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possibility of veto cells which were not evident in the in vitro experiments. This was not 
apparent initially in the in vitro experiments and may reflect the need to identify 
appropriate cells in the T cell compartment that may have undergone clonal expansion 
or, alternatively, identify cells that may perform this task outside of the mature T cell 
compartment such as NK cells. This is based on the results of the cotransfer 
experiments where the injection of recipient cells from the stable chimaeras of TU 
origin protected against the emergence of GVHD. 
In the TBI group, transplantation tolerance can be achieved by the manipulation of the 
donor bone marrow with TCD. This will adequately circumvent GVHD. However, the 
mechanism of transplantation tolerance is completely different to the TLI group. In this 
group, the emergence of suppressor cells was quite evident from the in vitro 
experiments in both the donor and recipient compartments. Furthermore, the 
identification of clonal expansion of Vp6 cells was unexpected. This may suggest that 
expansion occurs in the most reactive compartments and due to an inability to mount 
an appropriate response such as a cytotoxic response, results in a suppressive 
response. Whether this is a consequence of the conditioning regimen or the quality of 
the bone marrow transplant remains to be established. The precise mechanism of 
action of these cells need to be determined in future studies to establish their cytokine 
profile and possibly, the mechanism of function. 
In addition to the suppressive element of the tolerance, it is obvious that whilst this 
mechanism adequately depresses GVHD, it also diminishes the response to third party 
antigens and this may compromise the chimeric animal in responding to immunological 
challenges. This is substantiated in the in vitro responses where the MLC is depressed 
58 
to third party antigens upon addition of chimeric tolerant cells that were found to be 
expanded (the Vp6 cells). The precise magnitude of this is further substantiated in the 
response of the chimeric animal to donor (allogeneic) tumour. All chimeric mice infused 
with donor tumour cells succumbed to the tumour by 22 days. This raises the 
theoretical potential that BMT under these circumstances may expose the host to the 
potential of developing malignancies of donor origin with the same or worse outcome 
than would be anticipated in the donor. 
The conclusions that can be drawn from this study is that transplantation tolerance is 
influenced by various factors and the most important appear to be the quality of the 
BMT and the conditioning regimen used to prepare the recipient. Measures undertaken 
to minimise GVHD should be performed with caution especially in the context of 
malignancies as TCD used in this model resulted in suppressive mechanisms being the 
most prominent and this may account for the increase in relapse rates identified in 
recipients of TCD bone marrow in clinical transplantation. 
This study illustrates that whilst in vitro studies substantiate the role of pure 
mechanisms sustaining tolerance, the in vivo mechanisms are more complicated and 
diverse. Several mechanisms coexist to support transplantation tolerance. These are 
influenced by the various variables and, in this in vivo model, it was difficult to establish 
the precise mechanism of transplantation tolerance in the TLI group. However, the 
clinical implications of this study suggests that the more aggressive forms of 
conditioning may render the host susceptible as it encourages the emergence of a 
suppressive mechanism of tolerance which is attended with an inferior 
immunocompetence of the chimeric host. An alteration in the quality of the graft, such 
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as the infusion of T cells runs the risk of allowing GVHD to emerge with its own 
attendant risks. 
CONCLUSIONS 
The conclusions from this study suggest that the mechanisms that support 
transplantation tolerance are not necessarily beneficial to the host. Tolerance may be 
accompanied by immune-incompetence that places the recipient at risk of handling 
potentially benign conditions ineffectively. Of greater significance, there is also the risk 
of susceptibility to donor diseases that may be of greater risk to the recipient as a result 
of the depression in immune-competence. 
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CHAPTER 5 
THE GRAFT VERSUS LEUKAEMIA EFFECT (GVL) - EVALUATION OF 
THE MECHANISMS INDEPENDENT OF GRAFT VERSUS HOST 
DISEASE (GVHD) WITH DIFFERENT MECHANISMS OF 
TRANSPLANTATION TOLERANCE 
INTRODUCTION 
Bone Marrow Transplantation was used to salvage patients following more intensive 
cytoablative therapy. The principle that the transplantation regimen might be 
inadequate to completely eradicate leukaemic haematopoiesis and that the 
antileukaemic effect of infused marrow elements contributes to the ability of marrow 
transplantation to cure leukaemia was first proposed by Barnes et al in 1956
1
. Although 
their studies and the studies of subsequent investigators in murine models generally 
confirmed the existence of a Graft-Versus-Leukaemia (GVL) effect
2
, data in humans
was entirely indirect. Mathe et al3·
4 
rationalised early efforts at marrow transplantation
by invoking a GVL reaction, but evidence for this reaction was first provided by Weiden 




. They demonstrated that the likelihood of relapse
was substantially lower in patients with either acute or chronic Graft-Versus-Host­
Disease (GVHD) compared with unaffected patients. A higher relapse after syngeneic 
transplantation compared with allogeneic transplantation was shown retrospectively
7
and confirmed with a larger retrospective study
8
. Furthermore, a GVL effect was 
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inferred when recurrent leukaemia after marrow grafting regressed after a GVHD flare 
associated with the discontinuation of immunosuppression. 
It appears that GVHD and GVL may be mediated by overlapping but not identical 
subsets of cells. If these populations can be defined, they can be exploited in an 
immunotherapy regimen. 
Murine models of GVL support the concept that GVL and GVHD can be mediated by 
separate as well as identical cell populations but there may also be a leukaemia 




This led to the attempt to determine the mechanisms underlying the phenomenon of 
GVL without GVHD and identify the factors responsible for its emergence. Against this 
background we undertook the following study to determine 
1. The reproducibility of the GVL phenomenon in TU and TBI chimeras
2. The mechanisms underlying the effect
MATERIALS AND METHODS 
Mice: 6 - 12 week old mice were purchased. C3H/HeJ (H-2k, Thy 1.2, Mis 1 b/2a) and 
Balb/c (H-2d, Thy 1.1, Mis 1 b/2a) were purchased from Charles River (Sulzfield, 
Germany) and AKR/J (H-2k, Thy 1.2, Mis 1 a/2b) were purchased from Bomholtgard 
Breeding Center Ltd. (Ry, Denmark) 
Recipient mice were housed in plastic cages fitted with a filter cap, had sawdust 
bedding and housed in a pathogen free environment. Pellet chow and acidified drinking 
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water was the standard diet. Antibiotic (Tylan, Eli Lilly, Brussels, Belgium) was added to 
the drinking water 1 week prior to BMT and was continued for a week following it. 
Irradiation: Recipient mice received either 9.5 Gy Total Body Irradiation (TBI) as a 
single dose or Total Lymphoid Irradiation (TU) as 12 daily fractions (10 TU+ 2 TBI) of 
2 Gy each as described previously. Irradiation was delivered by a 60 Cobalt source 
(Gammatron, Siemens) at a low dose rate. The source to skin distance for the TBI was 
100 cm and, for mice receiving TU, was 80 cm. Mice receiving TU were anaesthetised; 
they were induced with Enflurane and then maintained in a prone position using 
Enflurane (Abbott, s.p.a., Campoverde-LT, Italy) delivered by a semi-closed inhalation 
anaesthetic system. The skull, long bones, kidneys, lungs and tail were shielded with 
lead blocks confining irradiation to the thymus, spleen, supra- and infradiaphragmatic 
lymph nodes. A maximum of 6 mice were irradiated simultaneoulsy. 
BMT: To prepare stable mixed chimeras with the elimination of GVHD, the recipient 
mice were reconstituted with donor cells in the following manner: 
TBI chimeras were prepared with 5 x 106 T cell depleted (TCD) allogeneic bone 
marrow. TCD was performed in vitro using Thy 1.1 (Serotech, Oxford, UK) or Thy 1.2 
(Sigma Chemie, GmbH, Drisenhof, Germany) antibodies and low toxic rabbit 
complement (Cedarlane, Hornby, Ontario, Canada). 
TU chimeras were prepared with 15 x 106 non-TCD allogeneic bone marrow. 
Bone marrow cells were harvested by flushing the shafts of the sacrificed donor 
animals with a solution of RPMI with antibiotics and 1 % heparin. The cells were washed 
twice with RPMI with added antibiotics. The viable cell count was determined by 
staining with Trypan blue and counted in a Burker haemocytometer. Cells were kept on 
63 
ice throughout. The cells were reconstituted to the relevant concentration such that 
0.25 ml was injected into the tail vein of the recipient, with the appropriate number of 
cells. 
Determination of chimerism and Vp6cel/s 
Chimerism was determined in a Flourescein Activated Cell Sorter (FACS) assay using 
Thy 1.1 (Serotech, Oxford, UK), and Thy 1.2 (Sigma Chemie, GmbH, Drisenhof, 
Germany) monoclonal antibodies (mAbs) conjugated with Phycoerythrin (PE) and 
Flourescein lsothiocyanate (FITC) respectively. These are lymphocyte markers 
specifically confined to either donor cells or recipient cells. 
Vp6 cells were evaluated in the CD4 window (Caltag lab, San Francisco) with Vp6 mAb 
(Pharmingen, Antwerp, Belgium) and percentages were estimated in the peripheral 
blood lymphocytes, thymus, splenic lymphocytes and lymph node lymphocytes. 
Mixed Lymphocyte Cultures (MLC): 
Responder cells: Single cell suspensions were made from the spleen/s of the 
responder mice by teasing them into fragments with forceps in RPMI on ice and then 
passed through a 100 µm cell strainer and washed twice with RPMI with added 
antibiotics. The viable cell count was determined. The cells (maximum of 10
8 cells) 
were incubated at 37
°C in a 5% CO2 incubator in 2 ml of RPMI with 5% foetal calf 
serum (FCS) in a nylon wool syringe. This syringe was previously washed with 50 ml 
of the same solution and kept in the incubator for a minimum of 1 hour prior to use. The 
enriched T cells were eluted. This was done by simply washing the non-adherent T 
cells from the syringe by passing 20 ml of the medium through the syringe and 
collecting the fluid under sterile conditions. The eluted cells were counted and made up 
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to a concentration of 5 x 106 cells/ml in RPMI with 10% FCS and 2ME 
(Mercaptoethanol). 
Stimulator cells: Single cell suspensions were prepared from the spleen/s of the mice 
as described as above. The cells were counted and made up to a concentration of 5 x 
106 cells/ml in RPMI with 10% FCS and 2ME. These cells were irradiated with 3000 
Rads and kept in the incubator until use. 
Chimeric cells: Cells of donor or recipient origin from the chimeric animals were 
isolated from single spleen cell suspensions by incubating the spleen cells with 
polyclonal antibodies* in RPMI with 20% FCS. After incubation, the cells were washed 
twice with RPMI to remove excess unbound antibodies and the cells were then 
incubated with low toxic rabbit complement for 45 minutes in a 37°C water bath. The 
cells were washed twice with RPMI. Cell counts were determined and the cells were 
reconstituted to yield a concentration of 2,5 x 106 cells/ml in RPMI with 10% FCS and 
2ME. These cells were irradiated with 1500 Rads and were added to the MLC to 
determine their influence on it. 
Vf36cells: These cells were isolated from single cell suspensions from the thymus of 
chimeric AKR mice using magnetic beads to isolate the cells and then bringing them to 
a concentration of 2.5 x 106 cells/ml. 
The cells were plated into 96 well flat bottom plates; 5 x 1 as responder cells and 5 x 1 a
s
stimulator cells were added to the wells in the experiments. Four experiment wells were 
performed and the mean values were used. Chimeric cells were added i.e. either of 
donor or recipient origin to determine their influence on this reaction again performed in 
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4 wells and the mean value taken. Control wells comprised cells from each group 
without the addition of other cells. 
The cells were incubated for a period of 96 hours in an incubator. Thereafter, 10:1 of 
[H3] Thymidine was added to each well and the cells were incubated for an additional 
16 hours after which the cells were harvested and the radioactivity measured. Results 
were interpreted as the mean of the experimental counts minus the sum of the mean 
counts of the relevant control cells. 
Polyclonal antisera: Polyclonal antibodies were raised by skin grafting the mice with 
skin from the allogeneic mice against which antibodies were to be raised. Once 
rejection occurred, the grafted mice were injected repeatedly with 5 x 106 donor 
haematopoeitic cells in Complete Freunds Adjuvant intraperitoneally until the 
development of ascites. The ascites was harvested, centrifuged, filtered by passage 
through a 100 µm filter and stored at -20°C. The concentration of the antibodies 
necessary was established by titration against a known concentration of cells. 
TUMOUR CELLS 
The BW 5147.3 tumour cell line, a lymphoma/ leukaemia cell line of AKR/J origin was 
injected intravenously at varying doses in the different experimental groups and the 
outcome was evaluated. 
COTRANSFER EXPERIMENTS 
Lethally irradiated AKR mice (10.5 Gy TBI) were reconstituted with 5 x 106 TCD 
syngeneic bone marrow and the groups were given tolerant splenocytes from the stable 




• depleted of CO4 cells,
• depleted of COB cells, or
• depleted of both CO4 and COB cells
one day following irradiation. 
One day later, the mice were injected with 106 BW 5147.3 tumour cells and the 
outcome in the various groups were monitored. 
Depletion was performed using magnetic beads (MACS) and the cells used in the 
cotransfer experimental cells were eluted by negative selection to prevent in vitro 
activation. 
IN VIVO EXPERIMENTS 
Early tumour innoculation 
There were 5 experimental groups:-
• 15 x 106 non TCO syngeneic BMT - TBI group
• 5 x 106 TCO semiallogeneic BMT - TBI group
• 15 x 106 non TCO semiallogeneic BMT + 5 x 106 syngeneic BMT - TBI group
• 15 x 106 non TCO syngeneic BMT
• 15 x 106 non TCO semiallogeneic BMT
Two days later 10
6 BW 5147.3 tumour cells were injected into the lateral tail vein of the 
mice. The delay in tumour innoculation was deliberate to ensure engraftment of the 
BMT. Simultaneous innoculation with tumour resulted in engraftment failure as 
observed previously. 
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Delayed tumour innoculation 
Two months after BMT, in groups similar to those described above, mixed chimaerism 
was confirmed in a FACS assay as already alluded to. Five animals from each group 
reconstituted with semiallogeneic BMT were sacrificed and the percentage composition 
of and the ratios of the CD4 : CDS was determined in both the peripheral blood and the 
spleen. The correlation to the outcome to the groups was determined to see if a 
relationship existed. 
At 2 months after confirmation of mixed chimaerism and clinical absence of GVHD, 3 x 
10
6 
BW 5147.3 tumour cells were injected into the lateral tail vein of the mice. 
RESULTS 
Early tumour innoculation 
The group of mice who were reconstituted with syngeneic BM all succumbed to tumour 
within 3 weeks after tumour innoculation. This was confirmed by histological evaluation 
of the tissues taken as soon as the mouse demised. This occurred in both the groups 
i.e. the group conditioned with TLI and TBI.
In contrast, animals reconstituted with semiallogeneic BM fared better than the animals 
reconstituted with syngeneic BM as well as those animals that were not irradiated but 
injected with tumour. 
Although both TBI groups reconstituted with semiallogeneic BM survived for 
significantly longer than the syngeneic groups, they in turn survived for a shorter period 
than the TLI group reconstituted with semiallogeneic BM and this was also statistically 
significant (fig 1 ). 
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Fig. 1 
EARLY TUMOUR INNOCULATION 
INTO AKR MICE 
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DAYS 
Survival Time Standard Error 95% Confidence Interval 
Mean: 14.60 2.62 ( 9.47, 19.73) 
Median: 18.00 2.24 ( 13.62, 22.38) 
Survival Time Standard Error 95% Confidence Interval 
Mean: 18.40 1.50 ( 15.45, 21.35) 
Median: 19.00 1.10 ( 16.85, 21.15) 
Survival Time Standard Error 95% Confidence Interval 
Mean: 19.60 2.01 ( 15.65, 23.55) 
Median: 20.00 2.19 ( 15.71, 24.29) 
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Survival Time Standard Error 
Mean: 31.60 3.60 
Median: 32.00 4.38 
Survival Time Standard Error 
Mean: 35.40 3.37 
Median: 38.00 6.57 
Survival Time Standard Error 
Mean: 52.80 
(Limited to 90.00 ) 
Median: 42.00 
Delayed tumour innoculation 
8.85 
2.19 
95% Confidence Interval 
( 24.54, 38.66) 
( 23.41, 40.59) 
95% Confidence Interval 
( 28.79, 42.01 ) 
( 25.12, 50.88) 
95% Confidence Interval 
35.46, 70.14 ) 
37. 71, 46.29 )
Delayed tumour innoculation allowed for the opportunity to confirm that the animals 
were mixed chimaeras and this was confirmed in a FACS assay of the peripheral blood 
using Thy 1.1 and Thy 1.2 antibodies coupled with PE and FITC respectively. All the 
animals reconstituted with semiallogeneic BM were found to be mixed chimaeras and 
the respective percentages of these are reflected below in table 1. 
TBI MICE TLI MICE 
%chimaerism 57,5 (48 - 62.7) 43.2 (31 - 52) 
As expected, the outcome in the respective groups of mice mirrored those in the early 
tumour innoculation group with the semiallogeneic group surviving for significantly 
longer than the syngeneic reconstituted group. TLI mice survived for significantly 
longer than TBI mice. Additionally, TBI mice reconstituted with non-TCD BM survived 
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longer than those reconstituted with TCD allogeneic BM, however, this did not achieve 
statistical significance (fig 2). 
Fig. 2 
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9.57, 21.23 ) 
7.26, 28.74) 
95% Confidence Interval 
12.59, 18.61 ) 
8.41, 25.59) 
95% Confidence Interval 
( 28.49, 39.51 ) 
( 28.85, 33.15) 
Survival Time Standard Error 95% Confidence Interval 
Mean: 40.40 5.39 ( 29.83, 50.97) 
Median: 43.00 5.48 ( 32.26, 53.74) 
Survival Time Standard Error 95% Confidence Interval 
Mean: 49.20 3.90 41.55, 56.85) 
(Limited to 60.00) 
Median: 52.00 13.15 26.24, 77.76) 
Cotransfer Experiments 
The cotransfer experiments were designed to attempt to establish the cell types that 
were responsible for effecting the GVL effect. As anticipated, the group that was denied 
allogeneic splenocytes succumbed the fastest to the tumour innoculation. 
Unexpectedly, all mice reconstituted with the splenocytes survived significantly longer 
than the group without allogeneic splenocytes. As expected, the group given the 
unmanipulated splenocytes survived the longest. Those mice with the T cell subgroups 
did not achieve any significant differences in survival. However, the necessity of T cells 
to support a GVL effect can be inferred from the results in that the group that was given 
splenocytes devoid of CD4 and COB cells fared worse than the groups that were given 
mature T cells (Fig 3). 
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Fig. 3 
COTRANSFER OF TOLERANT SPLENOCYTES 
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These results confirm that there is minimal NK activity against the tumour line by the 
transplanted bone marrow cells. However, cells primed with IL-2 have a significant 
cytotoxic activity mediated against the tumour cell line in vitro (fig. 4). 
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Fig. 4 












N Mean Deviation Minimum Maximum 
NKACT 8 2.4000 1.1784 1.10 3.80 
LAKACT 8 67.2500 31.0840 36.00 98.00 
CELL TYPE 8 1.5000 .5345 1.00 2.00 
Test Statisticsb 
NKACT LAKACT 
Mann-Whitney U .000 .000 
Wilcoxon W 10.000 10.000 
z -2.309 -2.323
Asymp. Sig. (2-tailed) .021 .020
b. Grouping Variable: CELL TYPE
78 
DISCUSSION 
Bone Marrow Transplantation is now a necessary and important therapy in the 
treatment of haematological malignancies. However, all the benefits that have been 
recognised do not occur in a predictable fashion. Additionally, the potential for adverse 
effects remain in clinical practice with occasional fatal outcomes. The only plausible 
solution is to unravel the mechanisms responsible for the various effects so that clinical 
manipulation can be safe, predictable and beneficial. 
This study undoubtedly confirms that BMT has an anti-tumoural effect that is allogeneic 
in origin. Furthermore, the mechanisms effecting the anti-tumour effect is not 
mandatorily accompanied by a GVHD effect. 
Of significance, the mechanisms sustaining transplantation tolerance play a significant 
role in the response that is effected. This in turn is influenced by the conditioning 
regimen. In mice conditioned with TBI, the GVL effect is significantly weaker than mice 
that are conditioned with TLI. To eliminate the bias of TCD, the method of Sykes et al 
was employed to sustain tolerance without TCD and, although there was a marginal 
improvement in survival, this did not attain statistical significance. 
The cotransfer experiments that were performed attest to the role of the T cells in 
playing a role in the GVL effect. However, this effect is present even in the absence of 
T cells but is best with mature splenocytes that were not manipulated. This suggests 
that the GVL effect in vivo is probably mediated in concert with a host of cells either 
playing direct roles or subsidary roles. The role of LAK cells may be important with T 
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cells perpetuating the response by facilitating the emergence of LAK cells. However, 
this is speculative and remains to be established. 
CONCLUSIONS 
The conclusions from this study are that allogeneic BMT does induce a GVL effect and 
can be attained without the emergence of GVHD. However, the response is influenced 
by both the conditioning regime and the quality of the BMT. T cells appear to be 
integral to the facilitation of a GVL effect. The effects however, may be to augment or 
induce the response rather than effect it. 
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CHAPTER 6 
PRESENCE OF INTRINSIC B LYMPHOCYTE TOLERANCE IN MIXED 
BUT NOT IN COMPLETE SEMIALLOGENEIC BONE MARROW 
CHIMERAS
1
The existence of intrinsic B lymphocyte transplantation tolerance was investigated in 
murine semiallogeneic complete and mixed bone marrow chimeras. Complete 
chimeras (CC), which were obtained by infusing 20x10
6 CS?BL/1 0xBALB/c) F1 
recipients, were repopulated for 100% with P1 lymphohaematopoietic cells. In mixed 
chimeras (MC), which were obtained by injection of 1Sx106 F1 BM cells, between 15% 
and 40% of F1 lymphohaematopoietic cells persisted after BM transplantation. Neither 
MC nor CC were able to develop significant T cell immunity (mixed lymphocyte 
reaction) or B cell immunity (1 gG alloantibodies) against the mismatched host antigens 
(BALB/c), despite repetitive immunizations. However, after immunization with third­
party cells (C3H}, the lgG alloantibodies raised cross-reacted with the host-type 
(BALB/c) antigens in the CC but not in the MC. This suggested that intrinsic B 
lymphocyte tolerance for host antigens had occurred in MC but not in the MC. This 
was further evidenced in transfer experiments using lethally irradiated CS?BL/10 mice 
reconstituted with purified control CS?BL/10 T Lymphocytes together with purified 
C57BU10 B lymphocytes isolated from CC or MC. Only the recipients reconstituted 
with B lymphocytes from CC, and not those from MC, produced anti-BALB/c lgG 
alloantibodies after immunization. These results show that intrinsic B lymphocyte 
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tolerance can be achieved after transplantation and that this depends on the presence 
of lymphohaematopoietic cells expressing the tolerogens. 
T lymphocytes can develop tolerance for allogeneic transplantation antigens based on 
mechanisms such as clonal deletion, clonal anergy, immunoignorance, and active 
suppression mechanisms that are also involved in the establishment of self tolerance 
(1-5). The long-proposed existence of intrinsic B lymphocyte tolerance (6) has been 
demonstrated in recent years using mice carrying rearranged immunoglobulin heavy 
and/or light chains (7,8). These experiments confirm that B lymphocytes that bind 
certain self or nee-self antigens may be tolerant by mechanisms such as clonal anergy 
(7), or exclusion from the peripheral lymphoid tissues (10). However, it remains 
unclear whether similar B cell tolerance may also be induced after allotransplantation, a 
situation that is very different from the transgenic mouse experiments because it 
involves multiple B cell clones with different affinities for numerous antigens. 
The latter question was addressed here in a model involving semiallogeneic bone 
marrow (BM*) transplantation in lethally irradiated mice. This model embraced a 
recapitulation of B lymphocyte ontogeny to see whether donor B lymphocytes could 
become tolerant for host-type transplantation antigens. The C57BL/10 into 
(C57BU1 OXBALB/c) F1 semiallogeneic combination model was used because 
immunodeficiency does not occur, whereas it is usually observed in fully allogeneic 
situations as a consequence of a lack of MHC restriction (11, 12). Indeed, in fully 
allogeneic combinations, donor T cells are restricted for host MHC during thymic 
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maturation, but because their antigen-presenting cells express donor MHC antigens to 
which T cells are not restricted, this may impair the interaction between the T 
lymphocytes and the antigen-presenting cells. The experiments presented here show 
that whereas donor T lymphocytes become tolerant for host MHC antigens in both 
mixed as well as complete chimeras, donor B lymphocytes are tolerized for host MHC 
antigens only in mixed chimeras. These experiments thus demonstrate that B 
lymphocyte transplantation tolerance can be attained, but this depends upon the 
presence of haematopoietic cells expressing the tolerogens. This finding may have 
implications for clinical transplantation. 
MATERIALS AND METHODS 
Induction of BM chimeras (MC) were constructed by infusing 15X10
6 
C578l/10 BM 
cells into lethally irradiated (10.5 Gy of total body irradiation) F1 recipient mice. In all 
MC, between 15% and 49% of host-type peripheral blood leukocytes were shown to 
persist after BM transplantation using a sensitive flow cytometry assay (13, 14). 
Complete chimeras (CC) were made by infusion of only 20X106 C57BL/10 BM cells. In 
CC, the presence of remaining host-type peripheral blood lymphocytes could not be 
demonstrated, despite multiple determinations. In all BM transplantation experiments, 
T cell depletion of the BM cells was achieved before infusion using anti-Thy 
monoclonal antibodies (Becton Dickinson, Mountain View, CA) and rabbit complement 
(Cedarlane, Ontario, Canada). After BM transplantation, the animals were kept in 
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specific pathogen-free conditions and were free from clinical and histological signs of 
graft-versus-host disease. 
Immunization of chimeras. Three months after BM transplantation, chimeric and 
control mice were immunized intraperitoneally once a week for 3 weeks with either 
50X106 irradiated (30 Gy) host-type (BALB/c), donor-type (C57BL/10), or third-party­
type (C3H) spleen cells (four mice per group for each antigenic stimulus). Ten days 
later, splenocytes were taken for mixed lymphocyte reaction (MLR) tests performed with 
immunizing cells as stimulator cells; sera were analyzed for the presence of antibodies 
directed against the immunizing cells. 
Mixed Lymphocyte Reaction. The MLR was performed by incubating 5X10
5 
responder spleen cells with 5X 105 irradiated (30 Gy) stimulator spleen cells for 96 hr at 
37°C. Proliferation was assayed by measuring the incorporation of radioactive [
3
HJ­
thymidine, and expressed as 
Stimulation Index = cpm of stimulated cells - cpm of unstimulated cells 
cpm of unstimulated cells 
Detection of lgG alloantibody formation. Alloantibody detection was performed 
using a modification of the flow cytometry crossmatch technique, as we described 
previously (14). Briefly 1X106 target spleen cells in 0.1 ml of saline solution were 
incubated for 20 min with 0.1 ml of various dilutions of serum from non-immunized and 
immunized mice. Thereafter, the cells were washed and incubated with 15 ul of 
Fluorescein lsothiocyanate-conjugated goat antimouse1 gG Fe (The Binding Site, 
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Birmingham, England) for 20 min. This second step detects only mouse 1 gG and 
hence does not stain mouse B cells as only a negligible fraction of them express 1 gG in 
mice. Serum titers were scored positive when they showed a significant shift in the 
mean fluorescein intensity by flow cytometry (FACScan, Becton Dickinson). 
Detection of alloantibodies directed against MHC class I or class II expressing 
cells. Because murine T lymphocytes express only MHC class I antigens and not MHC 
class II antigens, anti-MHC class I-directed antibodies were assayed by two-color flow 
cytometry using anti-L3T4 (Becton Dickinson) Phycoerythrin- coupled monoclonal 
antibody (directed against the murine CD4• T lymphocyte subset) and Flourescein 
lsothiocyanate-conjugaed anti-mouse 1 gG (Fe) monoclonal antibody. For assaying 
reactivity on class II-expressing cells, relevant anti-MHC class II-reacting anti-I-Ab, -I-Ad 
biotin-conjugated antibodies (PharMingen, San Diego, CA) were used. 
Purification of T and B lymphocytes. T lymphocytes and B lymphocytes were 
purified from splenocyte suspensions using a panning technique. Rabbit anti-mouse 
lg was first diluted to 10 ul per 10 ml of phosphate-buffered saline (PBS). 
Petri dishes (Falcon, Becton Dickinson, Belgium) were coated with 10 ml of this 
solution and kept at 4° C overnight. The following morning, the solution was poured off
and the Petri dishes washed three times with PBS. A single suspension of spleen cells 
was prepared in RPMI medium containing 10% fetal calf serum plus antibiotics. Six 
milliliters of medium containing 1OOX106 cells were added to each Petri dish and kept 
for 30 min at room temperature. Thereafter, the Petri dishes were rotated for 30 sec. 
To isolate the T cell population, non-adherent cells were poured into a second 
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antibody-coated Petri dish and kept for another 30 min at room temperature. 
Thereafter, the non-adherent cells were collected into a tube. To isolate the 8 cell­
enriched populations, the Petri dishes containing the adherent 8 cells were first 
washed three times with sterile PBS to remove remaining T cells. Thereafter, 5 ml of 
culture medium containing 10% normal mouse serum were added and incubated at 37° 
C for 1 hr in order to selectively dislodge the adherent 8 cells. 8 cells were then 
collected by pipetting into a tube and were washed two times with RPMI. This panning 
technique resulted in highly purified populations (>95% purity) of T and B lymphocytes. 
Where necessary, purification of donor lymphocytes from MC was done subsequently 
using C57BL anti-BALB/c alloantibodies and rabbit complement. After this procedure, 
no remaining BALB/c cells could be detected by flow cytometry. 
Transfer experiments. For the transfer experiments, lethally irradiated (12 Gy) control 
C57BL/10 mice were given 15X106 purified T cells and 15X106 purified B cells 
intravenously from various origins. One week later, the mice were immunized 
intraperitoneally once a week for 2 weeks with 1X108 irradiated (30 Gy) BALB/c or C3H 
spleen cells. A week after this, the serum was taken for alloantibody detection. 
Alloantibodies were scored using flow cytometry as described above. 
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RESULTS 
Cellular (MLR) and humora/ (alloantibody formation) immunity in BM chimeras after 
immunization with cells expressing donor (C57BU10), host (BALM/c), or third-party 
(C3H) antigens. Three months after BM transplantation, both MC and CC were fully 
immunocompetent as they raised normal cellular (MLR, Fig. 1 a) and humeral 
(alloantibody formation, Fig. 1 b) immune reactions after immunizing with third party 
(C3H) antigens. Concurrently, they were tolerant for host-type (BALB/c) and donor­
type (C57BL/10) antigens, as shown by the absence of a significant MLR response or 
alloantibody formation against these antigens. 
Cross-reactivity of anti-third-party (C3H) antiserum of MC and CC against mismatched 
host-type (BALB/c) antigens. As mentioned above, the apparent humeral tolerance of 
all chimeric mice may be due to a lack of T cell help (2), because they all showed MLR 
non-responsiveness against donor- and host-type antigens. To circumvent this 
absence of T cell help, we decided to exploit the principle of "T cell cross-help". This 
principle is based on the notion that T and B lymphocytes recognise different parts of 
the same antigen, called carrier and hapten, respectively (15). B lymphocytes with 
reactivity against the hapten part of host antigens may therefore persist in some 
chimeras, but remain quiescent due to T cell tolerance for the carrier part of the same 
antigens. However, after immunization with third-party (C3H0 antigens, the same N 
lymphocytes may pick up C3H antigens, the same B lymphocytes may pick up C3H 
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antigens that share hapten parts with BALB/c antigens but display C3H-specific carrier 
parts. Subsequently, these B lymphocytes may receive help from anti-C3H-directed T 
lymphocytes may receive help from anti-C3H-directed T lymphocytes and synthesize 
immunoglobulins recognizing cross- reacting BALB/c haptens. The possibility that 
intrinsic 8 lymphocyte tolerance may be absent as a consequence of the above was 
explored by investigating the cross-reactivity of the anti-C3H allosera of MC and CC 
against donor-type (C57BL/10) or host-type (BALB/c) cells (Fig.2). As expected, anti­
C3H antibodies from MC reacted strongly, as seen in a flow cytometry assay against 
C3H class I-expressing T cells (Fig.2c). However, cross-reactivity could be detected 
against neither C57BL/10 (Fig. 2, e and g) nor BALB/c (Fig.2,I and k) targets (one 
representative out of four similar experiments is shown). The outcome obtained with 
anti-C3H antibodies raised in CC was different, however. Again, as expected, this 
alloantiserum reacted with MHC class I-expressing (Fig. 2b) and MHC class II­
expressing (Fig. 2d) C3H cells and not with C57BL/10 (Fig. 2, f and h). However, a 
clear cross-reactivity against BALB/c targets expressing MHC class II antigens (Fig. 21) 
was seen (one representative out of five similar experiments is shown). This reactivity 
was directed at MHC antigens, as the latter serum was also positive on target cells 
from B10O2 mice that have the C57BL/10 background but are congeneic for the 
BALB/c MHC antigens (Fig. 2m). Interestingly, the anti-C3H antiserum from the CC 
reacted only with MHC class II-positive host cells and not with MHC class II antigens 
are predominantly expressed on haematopoietic cells (16), host-type MHC class II 
antigens are essentially absent in the CC, whereas MHC class I expression persists on 
non-haematopoietic cells. Therefore, anti-host cross-reacting antibodies from CC were 
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probably absorbed in vivo on class I MHC antigens but not on class II MHC antigens. 
This hypothesis was further supported by the transfer experiments discussed below. 
Transfer experiments show that B lymphocytes from MC develop intrinsic 
transplantation tolerance, whereas those from CC do not. To exclude the possibility 
that the absence of anti-host cross-reacting antibodies in the MC could have been due 
to absorption, because the MC host-type hemopoietic, and hence MHC class II as well 
as class I antigens, persist, purified donor B lymphocytes were isolated from MC and 
CC for transfer experiments (Fig. 3). These donor C57BL/10) B lymphocytes from 
normal control C57BU10 mice into heavily irradiated (12 Gy) control C57BL/10 mice. 
One week later, these animals were immunized with BALB/c or C3H cells. Figure 3 
shows the anti-BALB/c (Fig. 3a) and anti-C3H (Fig. 3b) alloantibody formation in 
C57BL/10 mice reconstituted with control C57BU10 T cells and C57BL/10 B 
lymphocytes isolated from MC. Figure 3a, line C, gives the anti-C3H response, as 
assessed with flow cytometry against target T lymphocytes (see Materials and 
Methods). For each experiment, negative (A lines) and positive (8 lines) control sera 
obtained from non-immunized and immunized control C57BL/10 mice, respectively, are 
shown as well. This experiment clearly shows that donor-type B lymphocytes isolated 
from MC are unable, even in the presence of non-tolerant control T lymphocytes, to 
produce alloantibodies directed at the mismatched antigens (BALB/c) of their original 
host (Fig. 3a, line C). Nevertheless, these B lymphocytes were immunocompetent, as 
shown by the significant anti-C3H response (Fig. 3b, line C) (one out of three similar 
experiments is shown). 
89 
The activity of the 8 lymphocytes isolated from CC is, however, very different, as shown 
in Figure 3c and Figure 3d. Indeed, mice reconstituted with 8 lymphocytes from CC 
were able to produce anti-BALB/c antibodies (Fig. 3c, line C) to the same extent as 
anti-C3H antibodies (Fig. 3d, line C). Again, flow cytometry profiles of negative and 
positive control sera are shown in lines A and B, respectively (one out of four similar 
experiments is shown). The absence of tolerance in the 8 cell compartment of CC was 
in contrast to the tolerance in their T cell compartment. Indeed, when in similar transfer 
experiments the T lymphocytes rather than the B lymphocytes from CC were transfused 
together with B lymphoctes from control C57BL/10 mice, the reconstituted mice were 
able to make anti-C3H antibodies (Fig. 3f) but not anti-BALB/c antibodies (Fig. 3f). 
In summary, all previous transfer experiments thus clearly demonstrate that intrinsic 8 
cell tolerance for host antigens had occurred in MC but not in CC. Moreover, as the 
flow cytometry data shown in Figure 3 were obtained from the T lymphocyte window 
and hence were likely directed against MHC class I (see Materials and Methods), B 
lymphocytes of CC are able to produce not only anti-host MHC class II alloantibodies, 
as previously shown in Figure 21, but also anti-host-type MHC class I alloantibodies 
(Fig. 3c. line C) 
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DISCUSSION 
The existence of intrinsic B lymphocyte tolerance has recently been unequivocally 
demonstrated in experiments involving mice with rearranged immunoglobulin genes 
and was shown to be based on various mechanisms, such as clonal deletion and clonal 
energy (7-9). The immunoglobulin coded for by these genes was directed at one 
specific known antigen. Here, we were interested to see whether intrinsic B cell 
tolerance could also be achieved in a more complex clinical situation, such as after BM 
transplantation, where obviously many B lymphocyte clones, all with various affinities 
for numerous antigens, have to be tolerant. In these experiments it is impossible to 
unravel the precise mechanisms involved. Indeed, to demonstrate clonal deletion, anti­
idiotypic antibodies, recognizing all the alloreactive antibodies with various affinities for 
the numerous alloantigens, should be available. This is obviously not feasible. A 
relative argument in favor of the mechanism of clonal anergy would be the progressive 
disappearance of the tolerance after transfer of the tolerized B lymphocytes in adoptive 
transfer experiments. 
Yet even this would not be a definite proof for anergy as recovery of B lymphocytes 
from haematopoietic stem cells in the new host may occur. What can be inferred is that 
the mechanism involved must be a very efficient and stable one, as the B lymphocyte 
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tolerance of the MC could not be broken despite multiple immunizations of the original 
hosts and the presence of immunocompetent T cells, as shown in the transfer 
experiments. 
A second important observation is that 8 lymphocyte tolerance was not achieved in CC. 
In the latter chimeras, host-type MHC class I antigens are expressed on epithelial cells, 
but host-type MHC class II antigens are constitutionally also present on thymic 
epithelial cells (17). Although it can be expected that the donor B cells encounter host­
type antigens in secreted form, this is clearly inadequate to result in 8 cell tolerance in 
CC. Indeed, from secreted antigens it is known that they either do not induce B cell
tolerance or induce anergy only (7, 10), which may easily wane (18). Alternatively, the 
donor 8 lymphocytes may encounter host antigens under polyvalent membrane bound 
form on host-type mesenchymal or haematopoietic cells (19). As CC by definition lack 
host-type haematopoietic cells, the absence of 8 cell tolerance in CC suggests that B 
lymphocyte transplantation tolerance depends on the presence of haematopoietic cells 
expressing the tolerogens. The question that can be raised is why donor B 
lymphocytes are not tolerant in CC whereas T cells are. Indeed, the CC showed MLR 
nonresponsiveness for host-type antigens, and, after purification, their T cells were 
unable to provide help in the transfer experiments for control 8 lymphocytes after 
immunization with host-type cells. The most likely explanation is that T lymphocytes 
mature in the thymus, where they encounter host-type thymic epithelial cells. Even in 
CC these cells are known to express host MHC class I and II antigens (17), and as 
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several reports indicate that thymic epithelial cells may impart tolerance (20,21 ), they 
are likely to be responsible for inducing T cell tolerance in CC. 
As discussed earlier, in order to circumvent the immune incompetence based on MHC 
restriction problems in CC, a semiallogeneic combination was used in the present 
experiments. We are currently exploring whether this simultaneous presence of 
allogeneic and syngeneic antigens on the tolerance-inducing F1 haematopoietic cells is 
a necessity for the B lymphocytes to develop transplantation tolerance. 
The current study is relevant for two important points raised recently in transplantation 
immunology. First, it was shown that CC have poor survival rates as compared with 
MC (22). This may be due to their persistent capacity to make antibodies against the 
host when challenged with foreign antigens that share haptens with the host, as shown 
in our CC immunized with C3H cells. Such as scenario may manifest during infections. 
Under these circumstances, CC have the potential to produce antibodies that cross­
react with host antigens and hence may develop chronic graft-versus-host disease. 
The finding of a more profound B cell tolerance in MC may be relevant for organ 
transplantation as well, as it has been claimed that transplant patients with the best 
outcomes, even after withdrawal of immunosuppressants, frequently show mixed 
chimerism (23). If the latter patients show better B cell transplantation tolerance, then 
the development of antibodies against the donor organ is likely to occur. 





together with C57BL/10 B lymphocytes from MC (B-MC). In panel b, line C shows the 
antibody formation in mice reconstituted with C57BL/l O B lymphocytes from CC (B-CC) 
together with control C57BL/10 T cells (T-con), respectively, after immunization with 
BALB/c (c, line C) and C3H (d, line C) cells. In panels e and f. the alloantibody formation of 
mice reconstituted with C57BL/l OT lymphocytes from CC (T-CC) together with control 
C57BL/l O B lymphocytes (B-con) after immunization with C3H cells (f, line C) or BALB/c 
cells ( e, line C) is given. The results are shown as flow cytometry profiles of l :5 diluted sera 




It has been previously demonstrated that two different conditioning regimens 
(TLI and TBI) are able to create a stable chimerism without signs of GVHD. In 
the current study, the mechanisms of tolerance that maintain chimerism and 
determine the behaviour of the chimeric animals against GVL and rejection 
reactions were investigated. 
In the mixed chimeric animals induced by TBI, the tolerance was not based on 
the mechanisms of deletion. On the contrary, an expansion of Vp6 positive cells 
of the recepient, that recognises the antibodies mlsa on the donor is present. 
Additionally, these cells behave as suppressor cells in the donor versus 
recipient and the recipient versus donor reactions and this was demonstrated in 
both the in vivo and in vitro experiments. This explains why the mixed chimeric 
animals did not lose their chimeric state after injection of splenocytes originating 
from the donor and were less effective in elaborating a GVL reaction after 
injection of tumour cells. 
In contrast, the mixed chimeras that were conditioned with TLI develop a 
tolerance mainly based on clonal deletion, in the absence of suppressor cells. 
This may explain why the TLI conditioned mice were unable to resist rejection 
and showed a strong GVL reaction. 
The mechanisms of transplantation tolerance is would be different depending on 
the type of conditioning regimen employed as well as the GVL effect. This partly 
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explains the resistance to rejection of chimeric animals and their capacity to 
facilitate GVL reactions. 
Complete chimeras (CC), which were obtained by infusing 20x10
6 
C57BL/1 0xBALB/c) 
F1 recipients, were repopulated for 100% with P1 lymphohaematopoietic cells. In 
mixed chimeras (MC), which were obtained by injection of 15x10
6 
F1 BM cells, between 
15% and 40% of F1 lymphohaematopoietic cells persisted after BM transplantation. 
Neither MC nor CC were able to develop significant T cell immunity (mixed lymphocyte 
reaction) or B cell immunity (1gG alloantibodies) against the mismatched host antigens 
(BALB/c), despite repetitive immunizations. However, after immunization with third­
party cells (C3H), the lgG alloantibodies raised cross-reacted with the host-type 
(BALB/c) antigens in the CC but not in the MC. This suggested that intrinsic B 
lymphocyte tolerance for host antigens had occurred in MC but not in the MC. This 
was further evidenced in transfer experiments using lethally irradiated C57BL/10 mice 
reconstituted with purified control C57BU10 T Lymphocytes together with purified 
C578L/10 8 lymphocytes isolated from CC or MC. Only the recipients reconstituted 
with 8 lymphocytes from CC, and not those from MC, produced anti-BALB/c lgG 
alloantibodies after immunization. These results show that intrinsic B lymphocyte 
tolerance can be achieved after transplantation and that this depends on the presence 
of lymphohaematopoietic cells expressing the tolerogens. 
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GENERAL PERSPECTIVES AND OPINION 
Bone Marrow Transplantation is a well-established therapeutic modality in 
clinical practice. Currently, the indications for its use remain pertinent to life 
threatening malignancies and congenital defects where it has made a significant 
impact on survival, but more importantly, on the quality of life of the individual. 
It is obvious that were it a safer procedure, its application to other less sinister 
conditions would be beneficial. Current clinical experience is guarded given the 
experience with BMT especially with respect to engraftment failure, the intensive 
care required during the period of engraftment as well as the later emergence of 
GVHD. 
Experimental data would suggest that the concept of transplantation tolerance 
as well as immunocompetence is attainable. However, this has yet to be 
predictably achieved in clinical medicine. The results of experimental data must 
be guarded in the face of the incongruity of homogenous subjects with respect to 
the results of in vitro and in vivo results as illustrated in these experiments. 
While mechanisms for transplantation tolerance are well-established, the 
mechanisms that prevail in individuals is influenced by factors beyond donor 
compatibility and includes the preconditioning regime and the quality of the bone 
marrow. This is relevant because it impacts on immunocompetence. 
Furthermore, whilst T cells appear to be pivotal in the various mechanisms that 
have been identified, the in vivo results would suggest that other cells may play 
important roles and elaborating the network of interaction remains elusive. 
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This study clearly demonstrated that differing conditioning regimes sustain 
different mechanisms of tolerance when GVHD has been eliminated and this has 
long-term consequences. 
It is hoped that the advent of newer immunosuppressive agents will allow for 
more predictable engraftment eliminating GVHD and, importantly, supporting 
transplantation tolerance that will allow for a superior immunocompetence rather 
than pose the risk of susceptibility to the recipient. 
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